References on the Administration of Growth Factors Using ALZET^® Osmotic Pumps

1. Epidermal Growth Factor

Q0699 Gampe,K., Brill,M.S., Momma,S., Goetz,M., Zimmermann,H. EGF induces CREB and ERK activation at the wall of the mouse lateral ventricles. Brain Research 2011; 1376(-;-):31-41. >>> Epidermal growth factor, recomb.; CSF, artificial; CSF/CNS; Mice; 1007D; 6 days; Controls received mp w/ vehicle; animal info (,ale, C57BL/6N, 8-10 wks old); artificial CSF formula.

Q0397 Aguirre,A., Rubio,M.E., Gallo,V. Notch and EGFR pathway interaction regulates neural stem cell number and self-renewal. Nature 2010; 467(-7313-):323-U101. >>> Ara-C; epidermal growth factor; Saline; CSF/CNS (surface); CSF/CNS; Mice; 5, 6 days; Controls received mp w/vehicle; animal info (Cnp-hEGFR); incorrectly stated model 1007.

Q0241 Im,S.H., Yu,J.H., Park,E.S., Lee,J.E., Kim,H.O., Park,K.I., Kim,G.W., Park,C.I., Cho,S.R. INDUCTION OF STRIATAL NEUROGENESIS ENHANCES FUNCTIONAL RECOVERY IN AN ADULT ANIMAL MODEL OF NEONATAL HYPOXIC-ISCHEMIC BRAIN INJURY. Neuroscience 2010; 169(-1-):259-268. >>> Brain-derived neurotrophic factor; epidermal growth factor; ara-C; CSF/CNS; Mice; 1002; 2 weeks; Controls received mp w/ PBS; ALZET brain infusion kit 3 used; animal info (ICR, 6 wks old); behavioral testing (rotarod performance, forelimb-use asymmetry test).

Q0061 Karimi-Abdolrezaee,S., Eftekharpour,E., Wang,J., Schut,D., Fehlings,M.G. Synergistic Effects of Transplanted Adult Neural Stem/Progenitor Cells, Chondroitinase, and Growth Factors Promote Functional Repair and Plasticity of the Chronically Injured Spinal Cord. Journal of Neuroscience 2010; 30(-5-):1657-1676. >>> Chondriotinase ABC; epidermal growth factor; fibroblast growth factor; platelet-derived growth factor; Penicillinase; saline; albumin, rat serum; CSF, artificial; gentamicin; BSA; CSF/CNS (intrathecal, subarachnoid space); Rat; 1007D; 7 days; Controls received mp w/ vehicle; animal info (female, Wistar, 250 g.); ALZET intrathecal catheter used (0007741).

P9944 Agrawal,A., Min,D.H., Singh,N., Zhu,H.H., Birjiniuk,A., von Maltzahn,G., Harris,T.J., Xing,D.Y., Woolfenden,S.D., Sharp,P.A., Charest,A., Bhatia,S. Functional Delivery of siRNA in Mice Using Dendriworms. ACS Nano 2009; 3(-9-):2495-2504. >>> RNA, small interfering; epidermal growth factor receptor; dendriworm, dye-labeled; RNA, small interfering, GFP, dendriworm, dye-labeled; CSF/CNS (intratumoral); Mice; 3, 7 days; Tissue perfusion (tumor); cancer (glioblastoma); incorrectly stated pump model 2007; Plastics One cannula used; animial info (Swiss Webster).

Q0793 Gonzalez-Perez,O., Romero-Rodriguez,R., Soriano-Navarro,M., Garcia-Verdugo,J.M., varez-Buylla,A. Epidermal Growth Factor Induces the Progeny of Subventricular Zone Type B Cells to Migrate and Differentiate into Oligodendrocytes. Stem Cells 2009; 27(-8-):2032-2043. >>> Epidermal growth factor; BSA; saline; CSF/CNS; Mice; 1007D; 7 days; Controls received mp w/ vehicle; animal info (adult, CD-1); schematic of pump and cannula placement, figure 4.

Q0798 Miksa,M., Wu,R.Q., Dong,W.F., Komura,H., Amin,D., Ji,Y.X., Wang,Z.M., Wang,H.C., Ravikumar,T.S., Tracey,K.J., Wang,P. Immature Dendritic Cell-Derived Exosomes Rescue Septic Animals Via Milk Fat Globule Epidermal Growth Factor VIII. Journal of Immunology 2009; 183(-9-):5983-5990. >>> Epidermal growth factor VIII, milk fat globule, recomb. murine; IV (jugular); Rat; 2001D; 20 hours; Controls received mp w/ PBS; immunology; animal info (male, Sprague-Dawley).

P9843 Oya,S., Yoshikawa,G., Takai,K., Tanaka,J.I., Higashiyama,S., Saito,N., Kirino,T., Kawahara,N. ATTENUATION OF Notch SIGNALING PROMOTES THE DIFFERENTIATION OF NEURAL PROGENITORS INTO NEURONS IN THE HIPPOCAMPAL CA1 REGION AFTER ISCHEMIC INJURY. Neuroscience 2009; 158(-2-):683-692. >>> Epidermal growth factor, recomb. human; fibroblast growth factor, recomb. human; Jag1, recomb. rat; S2188; DLL4, recomb. mouse; CSF, artificial, DMSO; CSF/CNS; Rat; 1003D; 1007D; 11 days; Controls received mp w/ vehicle; pumps replaced after 3 days; enzyme inhibitor (gamma secretase); animal info (male, Wistar, adult, 8 wks old, 280-320 g.); ischemia (cerebral); bilateral infusion; 10% DMSO used; brain tissue distribution.

P9320 De Toni,A., Zbinden,M., Epstein,J.A., Altaba,A.R.I., Prochiantz,A., Caille,I. Regulation of survival in adult hippocampal and glioblastoma stem cell lineages by the homeodomain-only protein HOP. Neural Development 2008; 3(-;-):U2-U13. >>> Epidermal growth factor; fibroblast growth factor, basic; RNA, small interfering; Saline, physiological; CSF/CNS; CSF/CNS (dentate gyrus); Rat; 1003D; 3 days; Controls received mp w/ control siRNA; cancer (glioblastoma); peptides; animal info (Swiss, HOP -/-, wt, adult); HOP or control siRNA was coupled to the cell permeant peptide, penetratin.

P8794 Louis,S.A., Rietze,R.L., Deleyrolle,L., Wagey,R.E., Thomas,T.E., Eaves,A.C., Reynolds,B.A. Enumeration of neural stem and progenitor cells in the neural colony-forming cell assay. Stem Cells 2008; 26(-4-):988-996. >>> Epidermal growth factor; ara-c; Saline; CSF/CNS; Mice; 1007D; 7 days; Controls received mp w/ vehicle; cyanoacrylate adhesive; animal info (adult, C57BL/6).

P8932 Oya,S., Yoshikawa,G., Takai,K., Tanaka,J.I., Higashiyama,S., Saito,N., Kirino,T., Kawahara,N. Region-specific proliferative response of neural progenitors to exogenous stimulation by growth factors following ischemia. NeuroReport 2008; 19(-8-):805-810. >>> Epidermal growth factor, recomb. human; fibroblast growth factor-2, recomb. human; insulin-like growth factor I, recomb. human; erythropoietin, recomb. rat; brain-derived neurotrophic factor, recomb. human; DDL4, recomb. mouse; CSF/CNS; Rat; 1003D; 3 days; Ischemia; animal info (male, Wistar, 8wks old, 280-300 g.); bilateral infusion.

P9520 Thatch,K.A., Schwartz,M.Z., Yoo,E.Y., Mendelson,K.G., Duke,D.S. Modulation of the inflammatory response and apoptosis using epidermal growth factor and hepatocyte growth factor in a liver injury model: a potential approach to the management and treatment of cholestatic liver disease. Journal of Pediatric Surgery 2008; 43(-12-):2169-2173. >>> Epidermal growth factor, recomb. human; human growth factor, recomb. human; IV; Rat; 7 days; Controls received mp w/ PBS; animal info (female, adult, Sprague Dawley, 200-250 g.).

P8632 Han,G.P., Li,L., Kosugi,I., Kawasaki,H., Tsuchida,T., Miura,K., Tsutsui,Y. Enhancement of susceptibility of adult mouse brain to cytomegalovirus infection by infusion of epidermal growth factor. Journal of Neuroscience Research 2007; 85(-13-):2981-2990. >>> Epidermal growth factor, mouse; PBS; CSF/CNS; Mice; 1003D; 3 days; Controls received mp w/ vehicle; peptides; animal info (female, BALB/c; 10, 25, and 70 wks old).

Q0248 Kolb,B, Morshead,C., Gonzalez,C., Kim,M., Gregg,C., Shingo,T., Weiss,S. Growth factor-stimulated generation of newcortical tissue and functional recovery after strokedamage to the motor cortex of rats. Journal of Cerebral Blood Flow and Metabolism 2007; 27(--):983-997. >>> Erythropoietin; epidermal growth factor; CSF, artificial; CSF/CNS; Rat; 2001; 7, 14 days; Controls received mp w/ vehicle; peptides; animal info (male, Long-Evans, 90-110 days old); ischemia (cerebral); behavioral testing (forelimb assymetry, forelimb inhibition (swimming), reaching); some animals received 7 days EGF.

P8705 Mizuno,M., Sotoyama,H., Narita,E., Kawamura,H., Namba,H., Zheng,Y.J., Eda,T., Nawa,H. A cyclooxygenase-2 inhibitor ameliorates behavioral impairments induced by striatal administration of epidermal growth factor. Journal of Neuroscience 2007; 27(-38-):10116-10127. >>> Epidermal growth factor, recomb. human; Saline; CSF/CNS (striatum); CSF/CNS (nucleus accumbens); Rat; 2002; 8-14 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; dose-response (fig. 1); peptides; multiple pumps per animal (2); post op. care (cefmetazon); animal info (male, Sprague-Dawley, 7-8 wks old, 300-380g); cannula position confirmed after completion of tests.

P8153 Bauer,S., Patterson,P.H. Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. Journal of Neuroscience 2006; 26(-46-):12089-12099. >>> Ara-C; leukemia inhibitory factor, recomb. mouse; epidermal growth factor, recomb. human; Saline; PBS; BSA; CSF/CNS; Mice; 1003D; 1007D; 1, 3, 6, 7, days; Controls received mp w/ vehicle; ALZET brain infusion kit 2 or 3 used; peptides; animal info (adult, male, C57BL/6J, 2-6 months old).

P7781 Grimaldi,P., Rossi,F. Lack of neurogenesis in the adult rat cerebellum after Purkinje cell degeneration and growth factor infusion. European Journal of Neuroscience 2006; 23(-10-):2657-2668. >>> Epidermal growth factor, recomb. human; fibroblast growth factor, basic; fibroblast growth factor 8b, recomb. mouse; Phosphate buffer; CSF/CNS; Rat; 2002; 1, 7, 14 days; Controls received mp w/ vehicle; peptides; animal info (Wistar albino, 200-250g, 2-3 months old).

P7677 Ivanov,A., Gerzanich,V., Ivanova,S., DenHaese,R., Tsymbalyuk,O., Simard,J.M. Adenylate cyclase 5 and Kca1.1 channel are required for EGFR up-regulation of PCNA in native contractile rat basilar artery smooth muscle. JOURNAL OF PHYSIOLOGY-LONDON 2006; 570(-1-):73-84. >>> Epidermal growth factor; AG-1478; angiotensin II; iberiotoxin; CSF, artificial; saline; CSF/CNS (intrathecal, cisterna magna); SC; Rat; 2001; 2004; 1,3 days; 4 weeks; Controls received mp w/ aCSF; cardiovascular; peptides; animal info (female, wistar, 275-325 g); angiotensin II disolved in saline and was subcutaneously delivered for 4 weeks using the 2004 model pump; AG-1478 is an EGFR inhibitor.

P7808 Karimi-Abdolrezaee,S., Eftekharpour,E., Wang,J., Morshead,C.M., Fehlings,M.G. Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury. Journal of Neuroscience 2006; 26(-13-):3377-3389. >>> Fibroblast growth factor, basic; epidermal growth factor; platelet-derived growth factor-AA; CSF, artificial; gentamycin; BSA; CSF/CNS (intrathecal); Rat; 1007D; 7 days; Peptides; animal info (female, Wistar, 250g., spinal cord injury, neural precursor cells transplantation).

P8024 Ohta,Y., Nagai,M., Nagata,T., Murakarni,T., Nagano,I., Narai,H., Kurata,T., Shiote,M., Shoji,M., Abe,K. Intrathecal injection of epidermal growth factor and fibroblast growth factor 2 promotes proliferation of neural precursor cells in the spinal cords of mice with mutant human SOD1 gene. Journal of Neuroscience Research 2006; 84(-5-):980-992. >>> Epidermal growth factor; fibroblast growth factor; PBS; CSF/CNS (intrathecal, lumbar region); Mice; 2001; 7 days; Controls received mp w/ vehicle; animal info (100 days old); no body weight changes after implantation of pumps; cannula used for IT cannulation.

P7683 Cellini,C., Xu,J., Buchmiller-Crair,T. Effect of epidermal growth factor on small intestinal sodium/glucose cotransporter-1 expression in a rabbit model of intrauterine growth retardation. Journal of Pediatric Surgery 2005; 40(-12-):1892-1897. >>> Epidermal growth factor, recomb. human; BSA; Rabbit (pregnant); 2ML1; ; Controls received mp w/ vehicle; animal info (New Zealand White, 3.2-4.5 kg).

P7424 Takemura,N.U. Evidence for neurogenesis within the white matter beneath the temporal neocortex of the adult rat brain. Neuroscience 2005; 134(-1-):121-132. >>> Epidermal growth factor; fibroblast growth factor-2; CSF, artificial; albumin, rat serum; CSF/CNS; Rat; 1003D; 3 days; Animal info (male, wistar, 11-12 weeks old, 260-280 g); Plastics One Cannula used.

P6924 Avissar,N.E., Ziegler,T.R., Toia,L., Gu,L., Ray,E.C., Berlanga-Acosta,J., Sax,H.C. ATBO/ASCT2 expression in residual rabbit bowel is decreased after massive enterectomy and is restored by growth hormone treatment. Journal of Nutrition 2004; 134(-9-):2173-2177. >>> Epidermal growth factor; Albumin; SC; Rabbit; 2ML2; 2 weeks.

P7178 Cellini,C., Xu,J., Arriaga,A., Buchmiller-Crair,T.L., Buchmiller-Crair,T.L. Effect of epidermal growth factor infusion on fetal rabbit intrauterine growth retardation and small intestinal development. Journal of Pediatric Surgery 2004; 39(-6-):891-897. >>> Epidermal growth factor, recomb.human; BSA; Intra-amniotic; Rabbit (pregnant); 2ML1; 7 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; no stress (see pg. 893); teratology; peptides; multiple pumps per animal (4).

P6989 Enwere,E., Shingo,T., Gregg,C., Fujikawa,H., Ohta,S., Weiss,S. Aging results in reduced epidermal growth factor receptor signaling, diminished olfactory neurogenesis, and deficits in fine olfactory discrimination. Journal of Neuroscience 2004; 24(-38-):8354-8365. >>> Epidermal growth factor, human recomb.; Ara-C; Saline; albumin, mouse serum; CSF/CNS; Mice; 1003D; 3 days; Controls received mp w/ vehicle; peptides.

P6377 Jin,K.L., Sun,Y.J., Xie,L., Childs,J., Mao,X.O., Greenberg,D.A. Post-ischemic administration of heparin-binding epidermal growth factor-like growth factor (HB-EGF) reduces infarct size and modifies neurogenesis after focal cerebral ischemia in the rat. Journal of Cerebral Blood Flow and Metabolism 2004; 24(-4-):399-408. >>> Epidermal growth factor, heparin binding; CSF, artificial; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; ischemia (cerebral).

P6493 Rooman,I., Bouwens,L. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan. Diabetologia 2004; 47(-2-):259-265. >>> Gastrin I, rat; epidermal growth factor, recomb. human; DMSO; saline, physiological; acetic acid; BSA; IP; Mice; 1007D; 1 week; Controls received no treatment; peptides; 8% DMSO.

top of page

2. Fibroblast Growth Factor

Q0891 MacMillan,K.S., Naidoo,J., Liang,J., Melito,L., Williams,N.S., Morlock,L., Huntington,P.J., Estill,S.J., Longgood,J., Becker,G.L., McKnight,S.L., Pieper,A.A., De Brabander,J.K., Ready,J.M. Development of Proneurogenic, Neuroprotective Small Molecules. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 2011; 133(-5-):1428-1437. >>> P7C3; analogue, P7C3; fibroblast growth factor-2; DMSO; cremophor EL; dextrose; water; CSF/CNS; Mice; 1007D; 7 days; Positive controls received mp w/ FGF-2; animal info (12 week old, C57BL/J6); neurodegenerative (Alzheimer's disease); 3% DMSO used.

Q0063 Hashish,M., Raghavan,S., Somara,S., Gilmont,R.R., Miyasaka,E., Bitar,K.N., Teitelbaum,D.H. Surgical implantation of a bioengineered internal anal sphincter. Journal of Pediatric Surgery 2010; 45(-1-):52-58. >>> Fibroblast growth factor-2, recomb.; PBS, sterile; SC; Mice; 1004; 25 days; Controls received mp w/ vehicle; tissue perfusion (internal anal sphincter); no stress (see pg. 57); good methods (pg. 53); animal info (female, C57BL/6, 8 wks old); "use of such pumps provided constant infusion over the postimplantation period without observed evidence of systemic effects and allowed increased efficiency of the drug owing to its proximity" pg. 57; operative photographs (pg. 54).

Q0308 Raghavan,S., Miyasaka,E.A., Hashish,M., Somara,S., Gilmont,R.R., Teitelbaum,D.H., Bitar,K.N. Successful implantation of physiologically functional bioengineered mouse internal anal sphincter. American Journal of Physiology-Gastrointestinal and Liver Physiology 2010; 299(-2-):G430-G439. >>> Fibroblast growth factor-2, human, recomb; SC; Mice; 1004; 21 days; Animal info (C57BL/6J female, specific pathogen-free, 8 wk old); ALZET PE catheter used; catheter connected to physiologically functional bioengineered mouse internal anal sphincter; tissue perfusion (internal anal sphincter).

Q0106 Sarruf,D.A., Thaler,J.P., Morton,G.J., German,J., Fischer,J.D., Ogimoto,K., Schwartz,M.W. Fibroblast Growth Factor 21 Action in the Brain Increases Energy Expenditure and Insulin Sensitivity in Obese Rats. Diabetes 2010; 59(-7-):1817-1824. >>> Fibroblast growth factor-21, recomb. human; BSA; CSF/CNS; Rat; 2002; 2 weeks; Controls received mp w/ vehicle; ALZET brain infusion kit 2 used; animal info (male, Wistar, 250-275 g); Research diets D12492; diabetes.

Q0482 Theurl,M., Schgoer,W., Albrecht,K., Jeschke,J., Egger,M., Beer,A.G.E., Vasiljevic,D., Rong,S., Wolf,A.M., Bahlmann,F.H., Patsch,J.R., Wolf,D., Schratzberger,P., Mahata,S.K., Kirchmair,R. The Neuropeptide Catestatin Acts As a Novel Angiogenic Cytokine via a Basic Fibroblast Growth Factor-Dependent Mechanism. Circulation Research 2010; 107(-11-):1326-1U95. >>> Antibody, fibroblast growth factor, b-, mouse; SC; Mice; 3, 4 weeks; Controls received mp w/control antibody; animal info (male, C57BL/6 wild-type, 12-15 mo old).

P9669 Sun,D, Bullock,M.R., McGinn,M.J., Zhou,Z., Altememi,N., Hagood,S., Hamm,R, Colello,R.J. Basic fibroblast growth factor-enhanced neurogenesis contributes to cognitive recovery in rats following traumatic brain injury. Experimental Neurology 2009; 216(-1-):56-65. >>> Fibroblast growth factor, b- recomb. human; CSF, artificial; CSF/CNS; Rat; 1007D; 7 days; Controls received mp w/ vehicle; ALZET brain infusion kit 2 used; animal info (male, Sprague Dawley, 3 months old, 300 g.).

P8930 Abbaspour,A., Takata,S., Sairyo,K., Katoh,S., Yukata,K., Yasul,N. Continuous local infusion of fibroblast growth factor-2 enhances consolidation of the bone segment lengthened by distraction osteogenesis in rabbit experiment. Bone 2008; 42(-1-):98-106. >>> Fibroblast growth factor-2, recomb. human; Bone (tibia); Rabbit; 2ML4; 14 days; half-life (p. 104) "relatively short"; tissue perfusion (tibia); animal info (male, 1.8-2.2 kg., osteotomized); polyvinyl catheter tubing used; pump image fig. 1e.

P8818 Conigliaro,A., Colletti,M., Cicchini,C., Guerra,M.T., Manfredini,R., Zini,R., Bordoni,V., Siepi,F., Leopizzi,M., Tripodi,M., Amicone,L. Isolation and characterization of a murine resident liver stem cell. CELL DEATH AND DIFFERENTIATION 2008; 15(-1-):123-133. >>> Fibroblast growth factor, bovine; Heparin; SC; Mice (nude); 10 days; Peptides.

P9180 Coskun,T., Bina,H.A., Schneider,M.A., Dunbar,J.D., Hu,C.C., Chen,Y.Y., Moller,D.E., Kharitonenkov,A. Fibroblast Growth Factor 21 Corrects Obesity in Mice. Endocrinology 2008; 149(-12-):6018-6027. >>> Fibroblast growth factor 21; SC; Mice; 2 weeks; Comparison of SC injections vs. mp; half-life (p. 6025) 1 hour in mice; peptides; animal info (male, DIO, ob/ob, C57BL/6); obesity; "approximately a 10-fold greater dose of FGF21 was required to achieve an equivalent weight reduction compared with FGF21 administration via ALZET pumps." pg. 6021.

R0266 Swan,E.E.L., Mescher,M.J., Sewell,W.F., Tao,S.L., Borenstein,J.I. Inner ear drug delivery for auditory applications. Advanced Drug Delivery Reviews 2008; 60(-15-):1583-1599. >>> Cisplatin; Sodium thiosulfate; Brain-derived neurotrophic factor; Fibroblast growth factor; D-JNKI-1; BN82270; Tetrodotoxin; Perilymph, artificial; Dexamethasone; Methylprednisone; Caroverine; Methionine, D-; Thiourea; Liposome, cationic; Neomycin; SC; Ear (round window membrane); Ear (cochlea); Ear (scala tympani); Ear; Guinea pig; 3, 7, 14, 28 days; Gene therapy; peptdies; no stress; enzyme inhibitor (peroxidase); stress/adverse reaction (see pg 1593) "Ref #161 found local trauma and inflammatory responses"; tissue perfusion (scala tympani, cochlea, round window membrane); comparison of middle ear injections vs. mp; Review, see pgs. 1587 - 1589, 1591, 1593 - 1595, refs #49, 50, 60, 63, 72, 75, 102, 104,180, 181, 194-201.

P9296 Zhao,H.D., Negash,L., Wei,Q., LaCour,T.G., Estill,S.J., Capota,E., Pieper,A.A., Harran,P.G. Acid promoted cinnamyl ion mobility within peptide derived macrocycles. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 2008; 130(-42-):13864-13866. >>> Fibroblast growth factor, recomb.; peptides, synthetic; cyclophane 17, meta-; CSF, artificial; CSF/CNS; Mice; 7 days; Controls received mp w/ vehicle or FGF; dose-response (fig. 3); animal info (adult, C57BL/6J).

P8702 Grumbles,R.M., Casella,G.T.B., Rudinsky,M.J., Wood,P.M., Sesodia,S., Bent,M., Thomas,C.K. Long-term delivery of FGF-6 changes the fiber type and fatigability of muscle reinnervated from embryonic neurons transplanted into adult rat peripheral nerve. Journal of Neuroscience Research 2007; 85(-9-):1933-1942. >>> Fibroblast growth factor-6, recomb. human; PBS; BSA; IM (medial gastrocnemius); Rat; 2ML4; 4 weeks; Controls received mp w/ vehicle; peptides; animal info (female, Fischer, adult).

P8478 Ma,T., Gutnick,J., Salazar,B., Larsen,M.D., Suenaga,E., Zilber,S., Huang,Z., Huddleston,J., Smith,R.L., Goodman,S. Modulation of allograft incorporation by growth factors over a prolonged continuous infusion of duration in vivo. Bone 2007; 41(-3-):386-392. >>> Fibroblast growth factor-2; osteogenic protein-1, recomb. human; Water, distilled; acetate buffer; Bone (tibia); Rabbit; 2004; 4,36 weeks; Controls received no treatment to contralateral side; long-term study; pumps replaced every 4 weeks, with 4 week rest periods between 4 week infusion periods; animal info (New Zealand white, 6-12 months old, 3.5-4.2 kg); peptides; OP-1 also known as bone morphogenic protein-7 (BMP-7); tissue perfusion (tibia); unique drug test chamber and bone harvest chamber used in conjunction with mp.

P8661 Miller,J.M., Le Prell,C.G., Prieskorn,D.M., Wys,N.L., Altschuler,R.A. Delayed neurotrophin treatment following deafness rescues spiral ganglion cells from death and promotes regrowth of auditory nerve peripheral processes: Effects of brain-derived neurotrophic factor and fibroblast growth factor. Journal of Neuroscience Research 2007; 85(-9-):1959-1969. >>> Brain-derived neurotrophic factor; fibroblast growth factor-1; Perilymph, artificial; albumin, guinea pig serum; Ear (scala tympani); Guinea-pig; 2002; 26 days; Controls received mp w/ vehicle; pumps replaced at day 13; peptides; tissue perfusion (scala tympani); animal info (male, female, pigmented, 250-300g, deafened).

P8631 Powell,JA Jr, Mousa,S.A. Neutrophil-Activating Protein-2- and Interieukin-8-Mediated Angiogenesis. Journal of Cellular Biochemistry 2007; 102(-2-):412-420. >>> Fibroblast growth factor-2, basic, human; penicillamine, S-nitroso N-acetyl; glutathione, S-nitroso N-acetyl; SC; Mice; 14 days; Peptides; animal info (male, C57BL/6, 6-8 wks old); SNAP and SNAG are nitric oxide donors.

P8658 Rai,K.S., Hattiangady,B., Shetty,A.K. Enhanced production and dendritic growth of new dentate granule cells in the middle-aged hippocampus following intracerebroventricular FGF-2 infusions. European Journal of Neuroscience 2007; 26(-7-):1765-1779. >>> Fibroblast growth factor-2; CSF, artificial; CSF/CNS; Rat; 2002; 14 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; good methods (p. 1766-1767); ALZET brain infusion kit used; cyanoacrylate adhesive; post op. care (tetracycline); animal info (male, F344, 12 months).

P8096 Gosain,A., Matthies,A.M., Dovi,J.V., Barbul,A., Gamelli,R.L., DiPietro,L.A. Exogenous pro-angiogenic stimuli cannot prevent physiologic vessel regression. Journal of Surgical Research 2006; 135(-2-):218-225. >>> Vascular endothelial growth factor 164, recomb.; platelet-dreived growth factor; fibroblast growth factor-2; Wound site; Mice; 2002; 11 days; Controls received mp w/ PBS; functionality of mp verified by VEGF levels in wound sponges, residual volume; stability verified by activity of residual VEGF in endothelial cell cord formation assay (fig.4); cardiovascular; peptides; animal info (female, BALB/c, 8-9 wks old, implanted sponge wounds); "The activity of VEGF isolated from the pump was comparable to fresh recombinant VEGF 164, confriming that the recombinant growth factors present in the mini-osmotic pump retain robust biological activity." (p.221).

P7799 Reimers,D., Herranz,A.S., az-Gil,J.J., Lobo,M.V.T., Paino,C.L., Alonso,R., Asensio,M.J., Gonzalo-Gobernado,R., Bazan,E. Intrastriatal infusion of liver growth factor stimulates dopamine terminal sprouting and partially restores motor function in 6-hydroxydopamine-lesioned rats. JOURNAL OF HISTOCHEMISTRY&CYTOCHEMISTRY 2006; 54(-4-):457-465. >>> Liver growth factor, rat; fibroblast growth factor, rat basic; Saline, physiological; albumin, rat; CSF/CNS (striatum); CSF/CNS; Rat; 2002; ; Controls received mp w/ vehicle, or no treatment; ALZET brain infusion kit used; peptides; neurodegenerative (Parkinson's disease); animal info (female, Sprague-Dawley, 220-250g., 6-OHDA induced lesions).

R0239 Richardson,R.T., Noushi,F., O'Leary,S. Inner ear therapy for neural preservation. AUDIOLOGY AND NEURO-OTOLOGY 2006; 11(-6-):343-356. >>> Nerve growth factor; NT-3; adenovirus; brain-derived neurotrophic factor; perilymph, artificial; glial-derived neurotrophic factor; ciliary neurotrophic factor; fibroblast growth factor, acidic; fibroblast growth factor-1; fibroblast growth factor-2; fibroblast growth factor, basic; Ear (cochlea); ear (scala tympani); Guinea-pig; 1,2,4,8 weeks; 15-60, 11-12, 26 days; Comparison of polymers, hydrogels, gene therapy, cell-based therapy, and injections vs. mp; long-term study; pumps replaced; no stress (see pg. 350); half-life (p. 344), short in blood; gene therapy; peptides; animal info (deafened); Table 2; "The mini-osmotic pump device is ideally suited to studying the effects of neurotrophic factors in the cochlea experimentally." (p. 350).

P8042 Wente,W., Efanov,A.M., Brenner,M., Kharitonenkov,A., Koester,A., Sandusky,G.E., Sewing,S., Treinies,I., Zitzer,H., Gromada,J. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006; 55(-9-):2470-2478. >>> Fibroblast growth factor-21; Saline; SC; Mice; 1002; 8 weeks; FGF-21 plasma levels taken; long-term study; pumps replaced every two weeks; animal info (C57BL/6, 8 weeks old); diabetes.

P8291 Won,S.J., Xie,L., Kim,S.H., Tang,H.D., Wang,Y.M., Mao,X.O., Banwait,S., Jin,K.L. Influence of age on the response to fibroblast growth factor-2 treatment in a rat model of stroke. Brain Research 2006; 1123(--):237-244. >>> Fibroblast growth factor-2; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; animal info (24 month old/3 month old, male, Fisher); ischemia (cerebral).

P8294 Yagi,H., Ueda,M., Jinno,H., Aiura,K., Mikami,S., Tada,H., Seno,M., Yamada,H., Kitajima,M. Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties. CANCER SCIENCE 2006; 97(-12-):1315-1320. >>> Fibroblast growth factor, basic; CL-RFN89; PBS; Mice (nude); ; Cancer (carcinoma); animal info (4 weeks old, female, Balb/C, nude); antiangiogenesis; tumor cells in right flank, agent is an insertional-fusion protein.

P7328 Kharitonenkov,A., Shiyanova,T.L., Koester,A., Ford,A.M., Micanovic,R., Galbreath,E.J., Sandusky,G.E., Hammond,L.J., Moyers,J.S., Owens,R.A., Gromada,J., Brozinick,J.T., Hawkins,E.D., Wroblewski,V.J., Li,D.S., Mehrbod,F., Jaskunas,S.R., Shanafelt,A.B. FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation 2005; 115(-6-):1627-1635. >>> Fibroblast growth factor-21; Saline; SC; Mice; 8 weeks; Controls received mp w/ vehicle; replacement therapy (diabetic, db/db); comparison of SC injections vs. mp (minipump used to study mitogenicity during longer exposure); long-term study.

P7568 Pieper,A.A., Wu,X.L., Han,T.W., Estill,S.J., Dang,Q.Y., Wu,L.C., Reece-Fincanon,S., Dudley,C.A., Richardson,J.A., Brat,D.J., McKnight,S.L. The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2005; 102(-39-):14052-14057. >>> Fibroblast growth factor, basic; CSF, artificial; CSF/CNS; Mice; 1007D; 4 days; Controls received mp w/ vehicle; animal info (male, 3 month old); also known as FGF2.

P7929 Tuereyen,K., Vemuganti,R., Bowen,K.K., Sailor,K.A., Dempsey,R.J. EGF and FGF-2 infusion increases post-ischemic neural progenitor cell proliferation in the adult rat brain. Neurosurgery 2005; 57(-6-):1254-1262. >>> Endothelial growth factor; fibroblast growth factor-2; CSF, artificial; BSA; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; ALZET brain infusion kit used; peptides; ischemia (cerebral); animal info (adult, male, SHR, 250-275 grams); MCAO; 0.1% BSA added.

P6920 Aronson,J. The Nicolas Andry Award - Modulation of distraction osteogenesis in the aged rat by fibroblast growth factor. Clinical Orthopaedics and Related Research 2004; (-425-):264-283. >>> Fibroblast growth factor, recomb. human; dihydrotestosterone; Sodium citrate; SC; bone (tibia); Rat; 1007D; 1002; 2002; 7, 14 days; Functionality of mp verified by residual volume; comparison of injections vs. mp; post op. care (heated cage/analgesics); pumps used for systemic or targeted delivery; silastic tubing used; "The pumps were well tolerated without inflammatory reaction, infection, or pain." (p. 273); picture of pump and catheter (radiograph image) p. 277, fig 10A-B; animal info (Sprague-Dawley).

P6944 Motoyoshi,K., Hyodo,M., Yamagata,T., Gyo,K. Restoring vocal fold movement after transection and immediate suturing of the recurrent laryngeal nerve with local application of basic fibroblast growth factor: An experimental study in the rat. Laryngoscope 2004; 114(-7-):1247-1252. >>> Fibroblast growth factor, basic; PBS; BSA; CSF/CNS (recurrent laryngeal nerve); Rat; 2002; 14 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; good methods (p. 1248); nerve infusion schematic (p. 1248).

top of page

3. Hepatocyte Growth Factor

Q0678 Thatch,K.A., Mendelson,K.G., Haber,M.M., Schwartz,M.Z. Growth Factor Manipulation of Intestinal Angiogenesis: A Possible New Paradigm in the Management of Inflammatory Bowel Disease. Journal of Surgical Research 2009; 156(-2-):245-249. >>> Hepatocyte growth factor, recomb. human; HCl, Tris; PBS; IV (jugular); Rat; 1002; 14 days; Controls received mp w/ saline; animal info (female, adult, Fisher).

P9298 Takeo,S., Takagi,N., Takagi,K., Date,I., Ishida,K., Besshoh,S., Nakamura,T., Tanonaka,K. Hepatocyte growth factor suppresses ischemic cerebral edema in rats with microsphere embolism. Neuroscience Letters 2008; 448(-1-):125-129. >>> Hepatocyte growth factor, recomb. human; Saline, physiological; CSF/CNS; Rat; 2001; 3 days; Controls received no treatment; peptides; ischemia (cerebral); animal info (male, Wistar, 220-250 g.).

P9077 Ye,L., Lewis-Russell,J.M., Sanders,A.J., Kynaston,H., Jiang,W.G. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 2008; 26(-2-):190-197. >>> Hepatocyte growth factor, recomb. human; NK4, recomb. human; SC; Mice (nude); 2004; 4 weeks; Cancer (prostate); animal info (athymic, male, CD-1, 4-6 wks old).

P8927 Chen,J.H., Wu,C.W., Kao,H.L., Chang,H.M., Li,A.F.Y., Liu,T.Y., Chi,C.W. Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor. Cancer Letters 2006; 239(-2-):263-270. >>> Hepatocyte growth factor; IP; Mice (SCID); 28 days; Controls received sham operation; pumps replaced after 14 days; cancer (gastric); peptides; post op. care (streptomycin, penicillin); animal info (male, SCID, 6-8 wks old, 20-25 g.).

P8925 Ye,L., Lewis-Russell,J.M., Davies,G., Sanders,A.J., Kynaston,H., Jiang,W.G. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. INTERNATIONAL JOURNAL OF ONCOLOGY 2007; 30(-2-):521-529. >>> Hepatocyte growth factor, recomb. human; SC; Mice (nude); 2004; 4 weeks; Controls received mp w/ BSA buffer; cancer (prostate); peptides; animal info (female, athymic, nude, CD-1, 4-6 wks old); HGF antagonist.

P8908 Ishigaki,A., Aoki,M., Nagai,M., Warita,H., Kato,S., Kato,M., Nakamura,T., Funakoshi,H., Itoyama,Y. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model. Journal of Neuropathology and Experimental Neurology 2007; 66(-11-):1037-1044. >>> Hepatocyte growth factor, recomb. human; PBS, sulfoxide; CSF/CNS (intrathecal, subarachnoid space); Rat (transgenic); 2002; 2004; 2, 4 weeks; Controls received mp w/ vehicle; dose-response (fig. 2); peptides; animal info (G93A Tg, 100 and 115 days old); neurodegenerative (ALS); "we examined the effects of continuous intrathecal delivery of human recombinant HGF (hrHGF) into Tg rats using implanted infusion pumps for selective and less invasive supply of HGF to the spinal cord." (p.1038).

P8815 Jin,H.K., Yang,R.H., Zheng,Z., Romero,M., Ross,J., Bou-Reslan,H., Carano,R.A.D., Kasman,I., Mai,E., Young,J., Zha,J.P., Zhang,Z.M., Ross,S., Schwall,R., Colbern,G., Merchant,M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Research 2008; 68(-11-):4360-4368. >>> Hepatocyte growth factor, human; Dextran sulfate; IP; Mice (nude); 1002; ; Controls received mp w/ vehicle; functionality of mp verified by human HGF serum levels; long-term study; pumps replaced every 12 to 14 days; cancer (pancreatic); peptides; animal info (female, nu/nu).

P8085 Date,I., Takagi,N., Takagi,K., Tanonaka,K., Funakoshi,H., Matsumoto,K., Nakamura,T., Takeo,S. Hepatocyte growth factor attenuates cerebral ischemia-induced increase in permeability of the blood-brain barrier and decreases in expression of tight junctional proteins in cerebral vessels. Neuroscience Letters 2006; 407(-2-):141-145. >>> Hepatocyte growth factor, recomb. human; CSF/CNS; Rat; 2001; 7 days; Controls received mp w/ physiological saline; peptides; ischemia (cerebral); animal info (male, Wistar, 180-220g, microsphere-induced cerebral embolism).

P8009 Niimura,M., Takagi,N., Takagi,K., Mizutani,R., Ishihara,N., Matsumoto,K., Funakoshi,H., Nakamura,T., Takeo,S. Prevention of apoptosis-inducing factor translocation is a possible mechanism for protective effects of hepatocyte growth factor against neuronal cell death in the hippocampus after transient forebrain ischemia. Journal of Cerebral Blood Flow and Metabolism 2006; 26(-11-):1354-1365. >>> Hepatocyte growth factor; Saline; CSF/CNS (right hippocampal region); Rat; 1003D; 3 days; Animal info (male, Wistar, 200-250 grams); ischemia (cerebral); tissue perfusion (hippocampal region).

P8008 Niimura,M., Takagi,N., Takagi,K., Mizutani,R., Tanonaka,K., Funakoshi,H., Matsumoto,K., Nakamura,T., Takeo,S. The protective effect of hepatocyte growth factor against cell death in the hippocampus after transient forebrain ischemia is related to the improvement of apurinic/apyrimidinic endonuclease/redox factor-1 level and inhibition of NADPH oxidase activity. Neuroscience Letters 2006; 407(-2-):136-140. >>> Hepatocyte growth factor; CSF/CNS (right hippocampal region); Rat; 1003D; 3 days; Animal info (male, Wistar, 200-250 grams); ischemia (cerebral); tissue perfusion (hippocampal region).

P7925 Tada,T., Zhan,H., Tanaka,Y., Hongo,K., Matsumoto,K., Nakamura,T. Intraventricular administration of hepatocyte growth factor treats mouse communicating hydrocephalus induced by transforming growth factor beta 1. NEUROBIOLOGY OF DISEASE 2006; 21(-3-):576-586. >>> Hepatocyte growth factor, recomb. human; PBS; BSA; CSF/CNS; Mice; 1007D; 1002; 7,14 days; Animal info (C57BL/6, 10-days old).

P7846 Niimura,M., Takagi,N., Takagi,K., Funakoshi,H., Nakamura,T., Takeo,S. Effects of hepatocyte growth factor on phosphorylation of extracellular signal-regulated kinase and hippocampal cell death in rats with transient forebrain ischemia. European Journal of Pharmacology 2006; 535(-1-3-):114-124. >>> Hepatocyte growth factor, recomb. human; Saline, physiological; CSF/CNS (hippocampus); Rat; 1003D; 1, 2, 3 days; 0.5, 1, 6 hours; Controls received mp w/ vehicle; dose-response (fig. 2); peptides; ischemia (cerebral); animal info (male, Wistar, 200-250g., transient forebrain ischemia by carotid artery occlusion); mp primed in 37 celsius saline.

P7668 Hasuike,S., Ido,A., Uto,H., Moriuchi,A., Tahara,Y., Numata,M., Nagata,K., Hori,T., Hayashi,K., Tsubouchi,H. Hepatocyte growth factor accelerates the proliferation of hepatic oval cells and possibly promotes the differentiation in a 2-acetylaminofluorene/partial hepatectomy model in rats. Journal of Gastroenterology and Hepatology 2005; 20(-11-):1753-1761. >>> Hepatocyte growth factor, recomb. human; PBS; IP; Rat; 7 days; Controls received mp w/ vehicle; functionality of mp verified by human HGF serum levels; replacement therapy (hepatectomy); half-life (pg. 1758)<3 min; animal info (male, Fisher, 8 wk. old).

P7654 Timmapuri,S.J., Otterburn,D.M., Arafat,H., Schwartz,M.Z. Hepatocyte growth factor increases glucagon immunoreactivity in jejunal cells during intestinal adaptation. Journal of Pediatric Surgery 2006; 41(-1-):150-153. >>> Hepatocyte growth factor; IV (jugular); Rat; 2002; 14 days; Controls received mp w/ saline; animal info (male, Sprague-Dawley, adult, 200-225 g); PE catheter used.

P7262 Ohda,Y., Hori,K., Tomita,T., Hida,N., Kosaka,T., Fukuda,Y., Miwa,H., Matsumoto,T. Effects of hepatocyte growth factor on rat inflammatory bowel disease models. Digestive Diseases and Sciences 2005; 50(-5-):914-921. >>> Hepatocyte growth factor, recomb. human; IP; Rat; 2001; 7 weeks; Controls received mp w/ PBS; functionality of mp verified by serum rhHGF levels.

P7047 Biswas,P., Roy,A., Gong,R.J., Yango,A., Tolbert,E., Centracchio,J., Dworkin,L.D. Hepatocyte growth factor induces an endothelin-mediated decline in glomerular filtration rate. American Journal of Physiology-Renal Physiology 2005; 288(-1-):F8-F15. >>> Hepatocyte growth factor; Saline; IV (jugular); Rat; 1 week; Controls received mp w/ vehicle; functionality of mp verified by plasma and urine HGF levels; comparison of acute IV infusions vs. mp; no stress (see pg. F12); post op. care (atipamezole).

P6951 Isogawa,K., Akiyoshi,J., Kodama,K., Matsushita,H., Tsutsumi,T., Funakoshi,H., Nakamura,T. Anxiolytic effect of hepatocyte growth factor infused into rat brain. NEUROPSYCHOBIOLOGY 2005; 51(-1-):34-38. >>> Hepatocyte growth factor; Ringer's solution; CSF/CNS; Rat; 1003D; 3 days; ALZET brain infusion kit used; behavioral study.

P6816 Date,I., Takagi,N., Takagi,K., Kago,T., Matsumoto,K., Nakamura,T., Takeo,S. Hepatocyte growth factor improved learning and memory dysfunction of microsphere-embolized rats. Journal of Neuroscience Research 2004; 78(-3-):442-453. >>> Hepatocyte growth factor, recomb. human; Saline, physiological; CSF/CNS; Rat; 2001; 7 days; Controls received sham ischemia operation and were HGF-untreated; dose-response (fig. 1); ischemia (cerebral); memory.

P6779 Date,I., Takagi,N., Takagi,K., Kago,T., Matsumoto,K., Nakamura,T., Takeo,S. Hepatocyte growth factor attenuates cerebral ischemia-induced learning dysfunction. Biochemical and Biophysical Research Communications 2004; 319(-4-):1152-1158. >>> Hepatocyte growth factor, recomb. human; Saline, physiological; CSF/CNS; Rat; 2001; 7 days; Controls received mp w/ vehicle; dose-response (fig 1); cardiovascular; ischemia (cerebral); learning/memory study.

top of page

4. Hepatocyte Growth Factor

R0142 O'Connor,W.J, Botti,T, Khan,S.N, Lane,J.M. The use of growth factors in cartilage repair.. Tissue Engineering In Orthopedic Surgery 2000; 31(-3-):399-409. >>> Insulin-like growth factor I; Hepatocyte growth factor; Fibroblast growth factor, basic; Transforming growth factor-B1;; ; No details provided about osmotic pump use. Broad overview of growth factors implicated in cartilage repair. Various animal models. ALZET one of several delivery methods..

P6700 Mori,T., Shimizu,A., Masuda,Y., Fukuda,Y., Yamanaka,N. Hepatocyte growth factor-stimulating endothelial cell growth and accelerating glomerular capillary repair in experimental progressive glomerulonephritis. NEPHRON EXPERIMENTAL NEPHROLOGY 2003; 94(-2-):E44-E54. >>> Hepatocyte growth factor, recomb. human; Saline; IP; Rat; 2ML1; 7 days; Controls received mp w/ vehicle; nephrology.

P6414 Arthur,L.G., Kuenzler,K.A., Schwartz,M.Z. Hepatocyte growth factor ameliorates inflammatory bowel disease in a rat model. JOURNAL OF GASTROINTESTINAL SURGERY 2003; 7(-8-):1062-1067. >>> Hepatocyte growth factor; Tris buffer; IV (jugular); Rat; 2002; 14 days; Peptides; one group of rats received HGF intravenously (jugular) and another received HGF intravenously via the terminal ileal.

P6413 Arthur,L.G., Schwartz,M.Z., Kuenzler,K.A., Birbe,R. Hepatocyte growth factor treatment ameliorates diarrhea and bowel inflammation in a rat model of inflammatory bowel disease. Journal of Pediatric Surgery 2004; 39(-2-):139-143. >>> Hepatocyte growth factor; Saline; IV (jugular); Rat; 2002; 14 days; Controls received mp w/ vehicle.

P6391 Dworkin,L.D., Gong,R.J., Tolbert,E., Centracchio,J., Yano,N., Zanabli,A.R., Esparza,A., Rifai,A. Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney International 2004; 65(-2-):409-419. >>> Hepatocyte growth factor; Saline; IV (jugular); Rat; 2002; 2 weeks; Controls received mp w/ vehicle; PE-50 used.

P6235 Kuenzler,K.A., Arthur,L.G., Schwartz,M.Z. A possible mechanism for prevention of intestinal programmed cell death after ischemia-reperfusion injury by hepatocyte growth factor pretreatment. Journal of Pediatric Surgery 2002; 37(-12-):1696-1699. >>> Hepatocyte growth factor, recomb. human; Tris buffer; IV (jugular); Rat; 1003D; 48-54 hours; Controls received mp w/ vehicle; peptides; ischemia (cardiac).

P5940 Davies,G., Mason,M.D., Martin,T.A., Parr,C., Watkins,G., Lane,J., Matsumoto,K., Nakamura,T., Jiang,W.G. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostat e tumor growth and angiogenesis in vivo. International Journal of Cancer 2003; 106(-3-):348-354. >>> Hepatocyte growth factor; NK4; BSA; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; cancer (prostate); NK4 (HGF/SF antagonist) is recomb. human.

P5892 Jin,H.K., Yang,R.H., Li,W., Ogasawara,A.K., Schwall,R., Eberhard,D.A., Zheng,Z., Kahn,D., Paoni,N.F. Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction. Journal of Pharmacology and Experimental Therapeutics 2003; 304(-2-):654-660. >>> Hepatocyte growth factor; Saline; heparin; IV (jugular); Rat; 2001; 6 days; Controls received mp w/ vehicle; functionality of mp verified by blood pressure taken&plasma levels taken; cardiovascular; peptides; recomb human HGF used; 50 U/ml of heparin.

P4766 Minami,H., Tada,K., Chowdhury,N.R., Chowdhury,J.R., Onji,M. Enhancement of retrovirus-mediated gene transfer to rat liver in vivo by infusion of hepatocyte growth factor and triiodothyronine. Journal of Hepatology 2000; 33(--):183-188. >>> Hepatocyte growth factor; Triiodothyronine;; Saline; Heparin, sodium;; IV (portal vein);; rat;; 24 hours;; Comparison of portal vein injections vs. mp; cancer; immunology; peptides; HGH used was recombinant human..

P4627 Minami,H., Tada,K, Chowdhury,N.R, Chowdhury,J.R, Morikazu,O. Persistent and delayed behavioral changes after nicotine treatment in adolescent rats. Journal of Hepatology 2000; 33(--):183-188. >>> Hepatocyte growth factor; NaCl; Heparin; IV; rat; 24 hours; comparison of IV injections vs. mp; peptides; heparin dose 50 U/kg.

P4446 Gupta,S, Rajvanshi,P, Aragona,E, Lee,C-D, Yerneni,P.R, Burk,R.D. Transplanted hepatocytes proliferate differently after CCl4 treatment and hepatocyte growth factor infusion. Am.J.Physiol.(Gastrointest.Liver Physiol.39) 1999; 276(--):G629-G638. >>> Hepatocyte growth factor; NaCl; Dextran sulfate; Intrasplenic; Rat; mice; 2001; 2ML1; 7 days; Tissue perfusion (spleen); peptides; recomb. human growth factor used; mice implanted w/2001; rats implanted w/2ML1.

P4432 Kaido,T, Yoshikawa,A, Seto,S-I, Yamaoka,S, Sato,M, Ishii,T, Imamura,M. Portal branch ligation with a continuous hepatocyte growth factor supply makes extensive hepatectomy possible in cirrhotic rats.. Hepatology 1998/9; 28(--):756-760. >>> Hepatocyte growth factor;; Phosphate buffer; Bovine serum albumin; NaCl;; IP;; rat;; 2001;; 6 days;; controls received mp w/vehicle; peptides; "...continuous HGF administration markedly improved the survival rate to 75%" (page 758); recomb. human HGF used..

P4115 Yamazaki,H., Inoue,T., Tang,J.T., Nose,T., Koizumi,M., Tanaka,E., Teshima,T., Ozeki,S., Nakamura,H., Inoue,T. Lack of effect of hepatocyte growth factor on bone marrow suppression induced by total body irradiation in the rat. Anticancer Res. 1997; 17(--):479-480. >>> Hepatocyte growth factor; Saline; IP; rat; 14 days; controls received mp w/saline; peptides; recomb. human HGF used; cancer.

P4002 Burr,A.W., Toole,K., Chapman,C., Hines,J.E., Burt,A.D. Anti-hepatocyte growth factor antibody inhibits hepatocyte proliferation during liver regeneration. J.Pathology 1998; 185(--):298-302. >>> Antibody, anti-hepatocyte growth factor monoclonal; PBS; IP; rat; 2001; 7 days; controls received mp w/IgG antibody; functionality of mp verified by antibody serum levels by ELISA; immunology.

P3874 Kato,Y., Yu,D., Lukish,J.R., Schwartz,M.Z. Hepatocyte growth factor enhances intestinal mucosal cell function and mass in vivo. J.Pediatr.Surg. 1997; 32(-7-):991-994. >>> Hepatocyte growth factor; IV (jugular); rat; 2002; 14 days; controls received mp w/saline; dose-response; peptides; recomb. human HGF used.

P3747 Kato,Y., Yu,D., Lukish,J.R., Schwartz,M.Z. Influence of luminal hepatocyte growth factor on small intestine mucosa in vivo. J.Surg.Res. 1997; 71(--):49-53. >>> Hepatocyte growth factor; intestine (small intestine); rat; 2002; 14 days; controls received mp w/ saline; dose-response; peptides; recomb. human HGF used.

P3739 Kato,Y., Yu,D., Schwartz,M.Z. Enhancement of intestinal adaptation by hepatocyte growth factor. J.Pediatr.Surg. 1998; 33(--):235-239. >>> Hepatocyte growth factor; IV (jugular); intraluminal (jejunum); rat; 2002; 14 days; controls received mp w/ saline; peptides; recomb. human HGF used.

P3738 Kato,Y., Yu,D., Schwartz,M.Z. Hepatocyte growth factor up-regulates SGLT1 and GLUT5 gene expression after massive small bowel resection. J.Pediatr.Surg. 1998; 32(--):13-15. >>> Hepatocyte growth factor; intraluminal (jejunum); rat; 2002; 14 days; controls received mp w/ saline; peptides; recomb. human HGF used.

top of page

5. Insulin-like Growth Factor

Q0683 Demonbreun,A.R., Fahrenbach,J.P., Deveaux,K., Earley,J.U., Pytel,P., McNally,E.M. Impaired muscle growth and response to insulin-like growth factor 1 in dysferlin-mediated muscular dystrophy. Human Molecular Genetics 2011; 20(-4-):779-789. >>> Insulin-like growth factor-I; 28 days; Controls received mp w/ PBS; animal info (Dysferlin null, wt).

Q0154 Apel,P.J., Ma,J.J., Callahan,M., Northam,C.N., Alton,T.B., Sonntag,W.E., Li,Z.Y. EFFECT OF LOCALLY DELIVERED IGF-1 ON NERVE REGENERATION DURING AGING: AN EXPERIMENTAL STUDY IN RATS. Muscle&Nerve 2010; 41(-3-):335-341. >>> Insulin-like growth factor-I, recomb. human; CSF/CNS (tibial nerve); Rat; 2004; 12 weeks; Controls received mp w/ saline; long-term study; pumps replaced after 6 weeks; animal info (Fischer 344 x Brown Norway, Sprague Dawley; 8 months old, 24 months old); diagram of pump with custom-made T-tube.

Q0120 Hewitt,S.C., Li,Y., Li,L.P., Korach,K.S. Estrogen-mediated Regulation of Igf1 Transcription and Uterine Growth Involves Direct Binding of Estrogen Receptor-alpha to Estrogen-responsive Elements. Journal of Biological Chemistry 2010; 285(-4-):2676-2685. >>> Insulin-like growth factor-1, synthetic long R3; Acetic acid; saline; IP; Mice; 18, 24 hours; Animal info (female, ERaKO KIKO, wt, 10 weeks old); peptides; replacement therapy (ovariectomy).

Q0345 Marino,G., Ugalde,A.P., Fernandez,A.F., Osorio,F.G., Fueyo,A., Freije,J.M.P., Lopez-Otin,C. Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2010; 107(-37-):16268-16273. >>> Insulin-like growth factor-1, human, recomb.; HCl; saline, isotonic, sterile; SC; Mice; 1004; 56 days; Animal info (transgenic, Zmpste24 metalloproteinase deficient); long-term study; pumps replaced after 28 days.

Q0153 Moreau,M.L., Sauvant,J., Moos,F., Palin,K. Brain insulin growth factor-I induces diuresis increase through the inhibition of arginin-vasopressin release in aged rats. NEUROBIOLOGY OF AGING 2010; 31(-3-):532-536. >>> Insulin-like growth factor-1, recomb. rat; CSF, artificial; CSF/CNS (third ventricle); Rat; 2ML4; 28 days; Animal info (male, Wistar, 3 months old, 645 g.); guide cannula used; aCSF recipe.

Q0057 Selvamani,A., Sohrabji,F. The Neurotoxic Effects of Estrogen on Ischemic Stroke in Older Female Rats Is Associated with Age-Dependent Loss of Insulin-Like Growth Factor-1. Journal of Neuroscience 2010; 30(-20-):6852-6861. >>> Insulin-like growth factor-1; JB-1; CSF, artificial; CSF/CNS; Rat (pregnant); 1007D; 7 days; Controls received mp w/ vehicle; ALZET brain infusion kit 2 used; cyanoacrylate adhesive; animal info (virgin, 3-4 months old, pregnant, 5-6 months old, retired, 9-11 months old); MCAO.

Q0078 Todd,B.J., Merhi,Z.O., Shu,J., Etgen,A.M., Neal-Perry,G.S. Hypothalamic Insulin-Like Growth Factor-I Receptors Are Necessary for Hormone-Dependent Luteinizing Hormone Surges: Implications for Female Reproductive Aging. Endocrinology 2010; 151(-3-):1356-1366. >>> JB-1; insulin-like growth factor-1; CSF, artificial; CSF/CNS (third ventricle); Rat; 2002; ; Controls received mp w/ vehicle; animal info (young, 3-4 months old, middle aged, 9-11 months old, adult, female, Sprague Dawley, ovariectomy); Plastics One cannula used; cannula placement verified post mortem by injecting dye into the cannula.

Q0466 Cittadini,A., Monti,M.G., Castiello,M.C., D'Arco,E., Galasso,G., Sorriento,D., Saldamarco,L., De Paulis,A., Napoli,R., Iaccarino,G., Sacca,L. Insulin-like growth factor-1 protects from vascular stenosis and accelerates re-endothelialization in a rat model of carotid artery injury. JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2009; 7(-11-):1920-1928. >>> Insulin-like growth factor-1; SC; Rat; ; Controls received mp w/saline; animal info (Sprague-Dawley, male, 210-250 g, ballon injury); 2.0 ul/h rate of infusion.

P9927 Cleveland,B.M., Weber,G.M., Blemings,K.P., Silverstein,J.T. Insulin-like growth factor-I and genetic effects on indexes of protein degradation in response to feed deprivation in rainbow trout (Oncorhynchus mykiss). American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2009; 297(-5-):R1332-R1342. >>> Insulin-like growth factor-1, recomb. human; IP; Fish; 1003D; ; Post op.care (triple antibiotic ointment); animal info (rainbow trout.1 year old); wound clips used.

P9701 Duman,C.H., Schlesinger,L., Terwilliger,R., Russell,D.S., Newton,S.S., Duman,R.S. Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behavioural Brain Research 2009; 198(-2-):366-371. >>> Insulin-like growth factor I, recomb. human; antibody, anti-IGF-I, polyclonal; Saline; SC; Mice; 1002; 2004; 14, 28 days; Controls received mp w/vehicle; animal info (male, C57BL/6, 10 wks old); behavioral testing (running wheel test, forced swim test).

P9605 Fan,Y., Menon,R.K., Cohen,P., Hwang,D., Clemens,T., DiGirolamo,D.J., Kopchick,J.J., Le Roith,D., Trucco,M., Sperling,M.A. Liver-specific Deletion of the Growth Hormone Receptor Reveals Essential Role of Growth Hormone Signaling in Hepatic Lipid Metabolism. Journal of Biological Chemistry 2009; 284(-30-):19937-19944. >>> Insulin-like growth factor I, recomb. human; SC; Mice; 2 weeks; Controls received mp/placebo; animal info (16 wks old, male, GHRLD).

Q0576 Serbedzija,P., Madl,J.E., Ishii,D.N. Insulin and IGF-I prevent brain atrophy and DNA loss in diabetes. Brain Research 2009; 1303(-;-):179-194. >>> Insulin; insulin-like growth factor-I; CSF/CNS; Rat; 12 weeks; Controls received mp w/ aCSF; animal info (Wistar, 275-300 g adult, 9 wks old, male, STZ-induced diabetes); long-term study; pumps replaced at two week intervals; ALZET brain infusion kit used; post op. care (Buprenorphine); cannula placement verified by injecting 20 ul dye through the catheter at time of assay.

Q0767 Traub,M.L., De Butte-Smith,M., Zukin,R.S., Etgen,A.M. Oestradiol and Insulin-Like Growth Factor-1 Reduce Cell Loss after Global Ischaemia in Middle-Aged Female Rats. Journal of Neuroendocrinology 2009; 21(-12-):1038-1044. >>> Insulin-like growth factor-I; Saline, sterile; CSF/CNS; Rat; 2004; 28 days; Controls received mp w/ vehicle; animal info (female, Sprague-Dawley, 9-11 mo old, adult, 300-500 g); functionality of mp verified by residual volume; ALZET brain infusion kit used; cannula placement verified by inspection of cryostat sectioning; neuroprotection.

P9922 Van Mieghem,T., van Bree,R., Van Herck,E., Deprest,J., Verhaeghe,J. Insulin-like growth factor-II regulates maternal hemodynamic adaptation to pregnancy in rats. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2009; 297(-5-):R1615-R1621. >>> Insulin-like growth factor II, human, recomb.; Saline; SC; Rat (pregnant); 2001; 7 days; Animal info (4 wks old, female, Sprague Dawley).

P9112 Chu,Y.W., Schmitz,S., Choudhury,B., Telford,W., Kapoor,V., Garfield,S., Howe,D., Gress,R.E. Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. Blood 2008; 112(-7-):2836-2846. >>> Insulin-like growth factor I; Sucrose; serum, mouse, PBS; SC; Mice; 4 weeks, 14 days; Pumps replaced after 2 weeks; peptides; animal info (C57BL/6, 8-12 wks old, thymectomized, PSGL-1KO).

P9784 Gehrig,S.M., Ryall,J.G., Schertzer,J.D., Lynch,G.S. Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage. Experimental Physiology 2008; 93(-11-):1190-1198. >>> Insulin-like growth factor I, LR-; Saline; HCl; SC; Mice; 1004; 4 weeks; Controls received mp w/ vehicle; functionality of mp verified by residual volume; animal info (male, BL/10, mdx, dystrophic, 8-10 wks old).

P9063 Iikubo,M., Kobayashi,A., Kojima,I., Ikeda,H., Sakamoto,M., Sasano,T. Excessive lateral dental arch expansion in experimentally developed acromegaly-like rats. Archives of Oral Biology 2008; 53(-10-):924-927. >>> Insulin-like growth factor I, recomb. human; Saline; SC; Rat; 2002; 4 weeks; Controls received mp w/ vehicle; peptides; animal info (10 wks old, male, Wistar, 200-236 g.).

P9251 Rosendahl,A.H., Holly,J.M.P., Celander,M., Forsberg,G. Systemic IGF-I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma. International Journal of Cancer 2008; 123(-6-):1286-1291. >>> Insulin-like growth factor I, recomb. human; Saline, sterile; albumin, mouse serum; SC; Mice (SCID); 1007D; 14 days; Controls received mp w/ vehicle; cancer (renal carcinoma); peptides; animal info (female, SCID CoB-17, 8-12 wks old, 20 g.).

P8871 Sferruzzi-Perri,A.N., Owens,J.A., Standen,P., Roberts,C.T. Maternal insulin-like growth factor-II promotes placental functional development via the type 2 IGF receptor in the guinea pig. PLACENTA 2008; 29(-4-):347-355. >>> Insulin-like growth factor II; Acetic acid; SC; Guinea-pig; 2002; 18 days; Controls received mp w/ vehicle; animal info (pregnant, female, 500g., 3-4 months old).

P8827 Sinkevicius,K.W., Burdette,J.E., Woloszyn,K., Hewitt,S.C., Hamilton,K., Sugg,S.L., Temple,K.A., Wondisford,F.E., Korach,K.S., Woodruff,T.K., Greene,G.L. An estrogen receptor-alpha; knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology 2008; 149(-6-):2970-2979. >>> Insulin-like growth factor I, R3-; Acetic acid; IP; Mice; 1003D; 16-24 hours; Controls received IP vehicle or E2 injections; replacement therapy (ovariectomy); peptides; animal info (female, C57/BL6 wt, ENERKI, 12 wks old); endocrinology.

P8922 Escartin,C., Boyer,F., Bemelmans,A.P., Hantraye,P., Brouillet,E. IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats. Neuroscience Letters 2007; 425(-3-):167-172. >>> Insulin-like growth factor I; nitropropionic acid, 3-; Acetic acid; BSA; SC; Rat; 2001; 2ML1; 5 days; Controls received mp w/ vehicle; functionality of mp verified by plasma glucose; dose-response (fig. 1, pg. 169); ALZET brain infusion kit used; animal info (Lewis, 400 g.); neurodegenerative (Huntington's Disease).

P8049 Kleinberg,D.L., Ruan,W.F., Yee,D., Kovacs,K.T., Vidal,S. Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice. Endocrinology 2007; 148(-3-):1080-1088. >>> Insulin-like growth factor I; growth hormone, bovine; insulin-like growth factor-1, binding protein; SC; Mice; 1007D; 7 days; Controls received mp w/ saline; peptides; animal info (ORX, 10 weeks old, male); drugs delivered alone or in combination.

P8370 Lopez-Lopez,C., Dietrich,M.O., Metzger,F., Loetscher,H., Torres-Aleman,I. Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease. Journal of Neuroscience 2007; 27(-4-):824-831. >>> Insulin-like growth factor I, recomb. human; SC; Mice; 1002; ; Controls received mp w/ saline; functionality of mp verified by serum IGF-I levels; peptides; animal info (C57BL/6J, APP/PS2, 6 month old); neurodegenerative (Alzheimer's disease).

P8836 Nichols,T.C., Busby,WH Jr, Merricks,E., Sipos,J., Rowland,M., Sitko,K., Clemmons,D.R. Protease-resistant insulin-like growth factor (IGF)-Binding protein-4 inhibits IGF-I actions and neointimal expansion in a porcine model of neointimal hyperplasia. Endocrinology 2007; 148(-10-):5002-5010. >>> Insulin-like growth factor-binding protein-4; Insulin-like growth factor-binding protein-4, mutated; Insulin-like growth factor-1, recomb. human; PBS; IA (carotid); IA (femoral); Pig; 21 days; Controls received mp w/ vehicle; cardiovascular; peptides; animal info (male, female, spotted Poland/China, 12 months old); protease resistant mutant form of IGFBP-4.

R0243 Sachdev,D., Yee,D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. MOLECULAR CANCER THERAPEUTICS 2007; 6(-1-):1-12. >>> Insulin-like growth factor binding protein-1, recomb. human; BSA; SC; Mice; 2 weeks; Controls received mp w/ vehicle; comparison of SC injections vs. mp; half-life (p. 4) "very short;" cancer (breast); peptides; animal info (athymic); review, see pg. 4-5; "IGFBP-1 had to be administered via osmotic pumps because of its very short half-life and it was ineffective on a twice-daily schedule in vivo." (p. 4).

P8682 Sferruzzi-Perri,A.N., Owens,J.A., Standen,P., Taylor,R.L., Robinson,J.S., Roberts,C.T. Early pregnancy maternal endocrine insulin-like growth factor I programs the placenta for increased functional capacity throughout gestation. Endocrinology 2007; 148(-9-):4362-4370. >>> Insulin-like growth factor I; insulin-like growth factor II, recomb. human; Acetic acid; SC; Guinea-pig; 2002; 18 days; Controls received mp w/ vehicle; functionality of mp verified by plasma levels; animal info (pregnant, female, 500g, 3-4 weeks); endocrinology.

P8385 Sferruzzi-Perri,A.N., Owens,J.A., Standen,P., Taylor,R.L., Heinemann,G.K., Robinson,J.S., Roberts,C.T. Early treatment of the pregnant guinea pig with IGFs promotes placental transport and nutrient partitioning near term. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 2007; 292(-3-):E668-E676. >>> Insulin-like growth factor I; Insulin-like growth factor II, recomb. human; Acetic acid; SC; Guinea-Pig (pregnant); 2002; 18 days; Controls received mp w/ vehicle; functionality of mp verified by IGF-I/II maternal circulation levels; peptides; animal info (female, pregnant, 500g., 3-4 months old, gestation days 20-38).

P8906 Todd,B.J., Fraley,G.S., Peck,A.C., Schwartz,G.J., Etgen,A.M. Central insulin-like growth factor 1 receptors play distinct roles in the control of reproduction, food intake, and body weight in female rats. Biology of Reproduction 2007; 77(-3-):492-503. >>> JB-1; insulin-like growth factor I, human; CSF, artificial; CSF/CNS; Rat; 1007D; 2002; 5, 7, 14 days; Controls received mp w/ vehicle; stress/adverse reaction: (see pg. 494) surgery led to a 10-15% loss of presurgical body weight, temporary disruption of estrous cycles; peptides; animal info (female, Sprague Dawley, 170-190 g.); IGF-1 receptor antagonist; cannula placement verified by dye injection at end of experiment; endocrinology.

P7584 Darnaudery,M., Perez-Martin,M., Belizaire,G., Maccari,S., Garcia-Segura,L.M. Insulin-like growth factor 1 reduces age-related disorders induced by prenatal stress in female rats. NEUROBIOLOGY OF AGING 2006; 27(-1-):119-127. >>> Insulin-like growth factor I, recomb. human; Saline; CSF/CNS; Rat; 2004; 21 days; Controls received mp w/ vehicle; ALZET brain infusion kit used; animal info (female, Sprague-Dawley 24 month old, 2 month old).

P9506 Fowlkes,JL. Effects of systemic and local administration of recombinant human IGF-I (rhIGF-I) on de novo bone formation in an aged mouse model. Journal of Bone and Mineral Research 2006; 21(-9-):1359-1366. >>> Insulin-like growth factor I, recomb. human; dye, methylene blue; PBS; SC; bone (tibia); bone (fibula); Mice; 1002; 14 days; Controls received mp w/ vehicle; functionality of mp verified by rhIGF-I serum levels; replacement therapy (mid-diaphyseal osteotomy (tibia, fibula)); peptides; post op. care (buprenex); tissue perfusion (tibia, fibula); animal info (male, C57BL/6, 18 months old).

P8170 Kobayashi,A., Iikubo,M., Kojima,I., Ikeda,H., Sakamoto,M., Sasano,T. Morphological and histopathological changes in tongues of experimentally developed acromegaly-like rats. Hormone and Metabolic Research 2006; 38(-3-):146-151. >>> Insulin-like growth factor I, recomb. human; Saline; SC; Rat; 2002; 4 weeks; Controls received mp w/ vehicle; peptides; animal info (male, Wistar, 10 weeks old, 225 grams).

P7855 Koopmans,G.C., Brans,M., Gomez-Pinilla,F., Duis,S., Gispen,W.H., Torres-Aleman,I., Joosten,E.A.J., Hamers,F.P.T. Circulating insulin-like growth factor I and functional recovery from spinal cord injury under enriched housing conditions. European Journal of Neuroscience 2006; 23(-4-):1035-1046. >>> Insulin-like growth factor I, recomb. human; insulin-like growth factor-1, anti-; Saline; SC; Rat; 2004; 4 weeks; Controls received mp w/ vehicle; no stress (see pg. 1039); peptides; animal info (female, Wistar, 11 wk. old).

P7866 Lupien,S.B., Bluhm,E.J., Ishii,D.N. Effect of IGF-I on DNA, RNA, and protein loss associated with brain atrophy and impaired learning in diabetic rats. NEUROBIOLOGY OF DISEASE 2006; 21(-3-):487-495. >>> Insulin-like growth factor I; Acetic acid; SC; Rat; 7-8 weeks; Controls received mp w/ vehicle; long-term study; pumps replaced every 18 days; peptides; neurodegenerative (Alzheimer's disease); animal info (male, Harlan Wistar, 10 wk. old).

P7467 Oldroyd,S.D., Miyamoto,Y., Moir,A., Johnson,T.S., El Nahas,A.M., Haylor,J.L. An IGF-I antagonist does not inhibit renal fibrosis in the rat following subtotal nephrectomy. American Journal of Physiology-Renal Physiology 2006; 290(-3-):F695-F702. >>> Insulin-like growth factor I, receptor antagonist; SC; Rat; 2002; 2004; 10, 90 days; Controls received mp w/ vehicle, or sham operation; dose-response (fig. 3); long-term study; pumps replaced every 4 weeks; stability verified by storage in mp for 4 weeks; peptides; animal info (male, wistar, chronic kidney disease, 200-300 g); IGF-I receptor antagonist (JB3); mp primed 4 hr in 37C isotonic saline.

P8339 Schertzer,J.D., Lynch,G.S. Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration after injury. Gene Therapy 2006; 13(-23-):1657-1664. >>> Insulin-like growth factor I; SC; Mice; 1002; 3, 10, 14 days; Controls received non-coding plasmid; functionality of mp verified by residual volume; comparison of gene transfer vs. mp; peptides; animal info (male, C57BL10, 12-14 weeks old, myotoxic tibialis anterior muscle injury).

P9141 Seigel,G.M., Lupien,S.B., Campbell,L.A., Ishii,D.N. Systemic IGF-I treatment inhibits cell death in diabetic rat retina. Journal of Diabetes and Its Complications 2006; 20(-3-):196-204. >>> Insulin-like growth factor I; streptozotocin; Acetate; SC; Rat; 2002; 8 weeks; Controls received mp w/ vehicle; long-term study; animal info (Wistar, 12 wks old); diabetes.

P8387 Serose,A., Salmon,A., Fiszman,M.Y., Fromes,Y. Short-term treatment using insulin-like growth factor-1 (IGF-1) improves life expectancy of the delta-sarcoglycan deficient hamster. JOURNAL OF GENE MEDICINE 2006; 8(-8-):1048-1055. >>> Insulin-like growth factor I, recomb. human; SC; Hamster; 2002; 19 days; Controls received mp w/ Saline; cardiovascular; peptides; animal info (male, Syrian wt or CHF147, 7-8 months old, 100-150g.).

P7829 Toth,C., Brussee,V., Zochodne,D.W. Remote neurotrophic support of epidermal nerve fibres in experimental diabetes. Diabetologia 2006; 49(-5-):1081-1088. >>> Insulin; insulin-like growth factor-1; Saline; SC; CSF/CNS (intrathecal, lumbar); Rat; 2002; 1 month; Controls received mp w/ vehicle; replacement therapy (stz-induced diabetes); pumps replaced after 2 weeks; peptides; animal info (male, Sprague-Dawley, 300-350g.); comparison of SC mp vs. IT mp.

P8968 Zeinoaldin,S., Swarts,J.J.M., Van de Heijning,B.J.M. Central application of IGF-1 postpones time of vaginal opening in normally fed, but not in food-restricted rats. Hormone Research 2006; 66(-4-):169-174. >>> Insulin-like growth factor I, recomb. human; Acetic acid; BSA; CSF/CNS; Rat; 2002; 14 days; Controls received mp w/ saline; peptides; animal info (Wistar, female, 23 days old, 45 g.); cannula position confirmed with Evans blue dye post mortem; endocrinology.

P7166 Cool,J.C., Dyer,J.L., Xian,C.J., Butler,R.N., Geier,M.S., Howarth,G.S. Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. GROWTH HORMONE&IGF RESEARCH 2005; 15(-1-):72-82. >>> Insulin-like growth factor I, recomb.human; Acetic acid; SC; Rat; 2002; 7 days; Controls received mp w/ vehicle, no stress (see pg. 75), cancer, peptides, orally administered IGF-1 degrades rapidly in the gastric environment.

P7607 Fernandez,A.M., Carro,E.M., Lopez-Lopez,C., Torres-Aleman,I. Insulin-like growth factor I treatment for cerebellar ataxia: Addressing a common pathway in the pathological cascade?. BRAIN RESEARCH REVIEWS 2005; 50(-1-):134-141. >>> Insulin-like growth factor I; SC; CSF/CNS; Rat; mice; 1 month; 2 weeks; Peptides; neurodegenerative (cerebellar ataxia); Review, pg. 138, ref #21; "This long-term delivery system increases therapeutically available IGF-1 at least 30-fold as compared to single subcutaneous injections" (p. 138).

P7405 Fruchtman,S., Simmons,J.G., Michaylira,C.Z., Miller,M.E., Greenhalgh,C.J., Ney,D.M., Lund,P.K. Suppressor of cytokine signaling-2 modulates the fibrogenic actions of GH and IGF-I in intestinal mesenchymal cells. American Journal of Physiology-Gastrointestinal and Liver Physiology 2005; 289(-2-):G342-G350. >>> Insulin-like growth factor I; growth hormone; Saline; SC; Mice (knockout); 5 days; Controls received mp w/ vehicle; peptides.

P7181 Hewitt,S.C., Collins,J., Grissom,S., Deroo,B., Korach,K.S. Global uterine Genomics in vivo: Microarray evaluation of the estrogen receptor alpha-growth factor cross-talk mechanism. MOLECULAR ENDOCRINOLOGY 2005; 19(-3-):657-668. >>> Epidemal growth factor; insulin-like growth factor-1, LR3-; Acetic acid; IP; Mice; 24 hours; Controls received mp w/ vehicle; comparison of IP injections vs. mp.

P7621 Narai,H., Nagano,I., Ilieva,H., Shiote,M., Nagata,T., Hayashi,T., Shoji,M., Abe,K. Prevention of spinal motor neuron death by insulin-like growth factor-1 associating with the signal transduction systems in SOD(G93A) transgenic mice. Journal of Neuroscience Research 2005; 82(-4-):452-457. >>> Insulin-like growth factor I, recomb. human; CSF, artificial; CSF/CNS (intrathecal, subarachnoid space, lumbar); Mice (transgenic); 2004; 5-10 weeks; Controls received mp w/ vehicle; dose-response (fig 1); long-term study; pumps replaced every 4 weeks; neurodegenerative (Amyotrophic Lateral Sclerosis); animal info (C57BL/6J, female); cannula used for IT placement.

P7142 Ruan,W.F., Monaco,M.E., Kleinberg,D.L. Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action. Endocrinology 2005; 146(-3-):1170-1178. >>> Insulin-like growth factor I, des(1-3); SC; Mice; 1007D; 1002; 5, 28 days; Controls received placebo; replacement therapy (IGF-I [-/-], oophorectomy); pumps replaced at day 14; cancer (breast); endocrinology.

P7346 Serose,A., Prudhon,B., Salmon,A., Doyennette,M.A., Fiszman,M.Y., Fromes,Y. Administration of insulin-like growth factor-1 (IGF-1) improves both structure and function of delta-sarcoglycan deficient cardiac muscle in the hamster. Basic Research In Cardiology 2005; 100(-2-):161-170. >>> Insulin-like growth factor I, recomb. human; Saline; SC; Hamster; 2004; ; Controls received mp w/ vehicle; peptides.

P7939 Shi,L., Linville,M.C., Tucker,E.W., Sonntag,W.E., Brunso-Bechtold,J.K. Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus. Cerebral Cortex 2005; 15(-5-):571-577. >>> Insulin-like growth factor I, recomb. human; Saline; CSF/CNS; Rat; 2002; 28 days; Controls received mp w/ vehicle; pumps replaced after 14 days; no stress (see pg. 573); ALZET brain infusion kit used; petides; animal info (male, fischer, Brown Norway F1, 29 months old); memory; aging.

P7350 Slagter,B.J., Kittilson,J., Sheridan,M.A. Expression of somatostatin receptor mRNAs is regulated in vivo by growth hormone, insulin, and insulin-like growth factor-I in rainbow trout (Oncorhynchus mykiss). REGULATORY PEPTIDES 2005; 128(-1-):27-32. >>> Growth hormone, recomb. bovine; insulin, recomb. bovine; insulin-like growth factor. recomb. human; NaCl; IP; Fish (rainbow trout); 1007D; 21 days; Controls received mp w/ vehicle; peptides; post op. care (topical antibiotic ointment); at 14 degrees celsius, the 1007D infuses at 0.14 ul/hr for approximately 21 days.

P7336 Zhu,Z.J., Jiang,W.Q., McGinley,J., Wolfe,P., Thompson,H.J. Effects of dietary energy repletion and IGF-1 infusion on the inhibition of mammary carcinogenesis by dietary energy restriction. MOLECULAR CARCINOGENESIS 2005; 42(-3-):170-176. >>> Insulin-like growth factor I; HCL; SC; Rat; 2001; 8 days; Peptides.

P6798 Brussee,V., Cunningham,F.A., Zochodne,D.W. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 2004; 53(-7-):1824-1830. >>> Insulin, human; FITC-Insulin; Insulin-like growth factor I; antibody, polyclonal anti-rat insulin; dye, india ink; antibody, polyclonal anti-albumin; Saline; SC; CSF/CNS (intrathecal); Rat; 2, 4 weeks; Controls received mp w/ vehicle or anti-albumin Ab; functionality of mp verified by dye; replacement therapy (streptozotocin induced diabetes); india ink used to confirm catheter placement and intrathecal delivery.

P6835 Cao,W.M., Murao,K., Imachi,H., Yu,X., Dobashi,H., Yoshida,K., Muraoka,T., Kotsuna,N., Nagao,S., Wong,N.C.W., Ishida,T. Insulin-like growth factor-i regulation of hepatic scavenger receptor class BI. Endocrinology 2004; 145(-12-):5540-5547. >>> Insulin-like growth factor I; Rat; 2001; 7 days; Controls received mp w/ vehicle; functionality of mp verified by plasma IGF-I concentrations.

P6932 Escartin,C., Boyer,F., Bemelmans,A.P., Hantraye,P., Brouillet,E. Insulin growth factor-I protects against excitotoxicity in the rat striatum. NeuroReport 2004; 15(-14-):2251-2254. >>> Insulin-like growth factor, recomb. human; BSA; acetic acid; CSF/CNS; Rat; 1003D; 2 days; ALZET brain infusion kit; neurodegenerative (Huntington's disease); dental cement used.

P6519 Haddad,F., Adams,G.R. Inhibition of MAP/ERK kinase prevents IGF-I-induced hypertrophy in rat muscles. Journal of Applied Physiology 2004; 96(-1-):203-210. >>> PD-98059; insulin-like growth factor I; IM (plantaris); Rat; 2002; 14 days; Controls received no treatment to the contralateral muscle; functionality of mp verified by residual volume aspiration&measurement; no stress (see pg.205); good methods p. 203; enzyme inhibitor (MAPK/ERK kinase); mp primed in sterile saline @ 37 degrees Celsius.

P6757 Iikubo,M., Ikeda,H., Kobayashi,A., Kojima,I., Hashimoto,K., Sakamoto,M., Sasano,T. Insulin-like growth factor-I stimulates acromegaly-like specific mandibular enlargement in rats. Hormone and Metabolic Research 2004; 36(-10-):696-701. >>> Insulin-like growth factor I, recomb. human; Saline; SC; Rat; 2002; 4 weeks; Controls received mp w/ vehicle; functionality of mp verified by human IGF-I serum levels; peptides.

P6929 Jevdjovic,T., Maake,C., Eppler,E., Zoidis,E., Reinecke,M., Zapf,J. Effects of insulin-like growth factor-I treatment on the endocrine pancreas of hypophysectomized rats: comparison with growth hormone replacement. European Journal of Endocrinology 2004; 151(-2-):223-231. >>> Insulin-like growth factor, recomb. human; Acetic acid; IP; Rat; 2001; 2 days; Controls received mp w/ vehicle; IGF plasma levels taken; peptides.

P6848 Kamegai,J., Tamura,H., Shimizu,T., Ishii,S., Tatsuguchi,A., Sugihara,H., Oikawa,S., Kineman,R.D. The role of pituitary ghrelin in growth hormone (GH) secretion: GH-releasing hormone-dependent regulation of pituitary ghrelin gene expression and peptide content. Endocrinology 2004; 145(-8-):3731-3738. >>> Growth hormone, rat; insulin-like growth factor-1, recomb. human; Saline; SC; Rat; 1003D; 72 hours; Controls received mp w/ vehicle; peptides.

P6858 Lopez-Lopez,C., LeRoith,D., Torres-Aleman,I. Insulin-like growth factor I is required for vessel remodeling in the adult brain. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2004; 101(-26-):9833-9838. >>> Insulin-like growth factor I; antibody, anti-IGF I; serum, rabbit; SC; Mice; 2001; 2 weeks; 28 days; Controls received mp w/ saline or serum; comparison of microsphere injections vs. mp.

P6615 Sakata,T., Wang,Y.M., Halloran,B.P., Elalieh,H.Z., Cao,J., Bikle,D.D. Skeletal unloading induces resistance to insulin-like growth factor-I (IGF-I) by inhibiting activation of the IGF-I signaling pathways. Journal of Bone and Mineral Research 2004; 19(-3-):436-446. >>> Insulin-like growth factor; uridine, bromodeoxy-; Sodium succinate; DMSO; propylene glycol; SC; Rat (dwarf); 14 days; BrdU was dissolved in 50% DMSO/50% propylene glycol for labeling of osteocytes; pump model not listed.

P6839 Thordarson,G., Slusher,N., Leong,H., Ochoa,D., Rajkumar,L., Guzman,R., Nandi,S., Talamantes,F. Insulin-like growth factor (IGF)-I obliterates the pregnancy-associated protection against mammary carcinogenesis in rats: evidence that IGF-I enhances cancer progression through estrogen receptor-alpha activation via the mitogen-activated protein kinase pathway. BREAST CANCER RESEARCH 2004; 6(-4-):R423-R436. >>> Insulin-like growth factor I, recomb. human; SC; Rat (pregnant); 60 days; Controls received mp w/ vehicle or no treatment; functionality of mp verified by IGF-I plasma levels; cancer (mammary).

P6838 Thordarson,G., Semaan,S., Low,C., Ochoa,D., Leong,H., Rajkumar,L., Guzman,R.C., Nandi,S., Talamantes,F. Mammary tumorigenesis in growth hormone deficient spontaneous dwarf rats; effects of hormonal treatments. Breast Cancer Research and Treatment 2004; 87(-3-):277-290. >>> Insulin-like growth factor I, recomb. human; SC; Rat; 21 weeks; 10 days; Controls received no treatment; replacement therapy (GH deficient, dwarf); long-term study; cancer (mammary); peptides.

P6796 Xian,C.J., Howarth,G.S., Cool,J.C., Foster,B.K. Effects of acute 5-fluorouracil chemotherapy and insulin-like growth factor-I pretreatment on growth plate cartilage and metaphyseal bone in rats. Bone 2004; 35(-3-):739-749. >>> Insulin-like growth factor I, recomb. human; Acetic acid; SC; Rat; 7 days; Controls received mp w/ vehicle; cancer; osteoporosis.

top of page

6. Nerve Growth Factor

Q0685 Toda,S., Sakai,A., Ikeda,Y., Sakamoto,A., Suzuki,H. A local anesthetic, ropivacaine, suppresses activated microglia via a nerve growth factor-dependent mechanism and astrocytes via a nerve growth factor-independent mechanism in neuropathic pain. Molecular Pain 2011; 7(-;-):U1-U11. >>> Nerve growth factor, beta, recomb., rat; Saline; albumin, rat, serum; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle; animal info (male, Sprague-Dawley, 220-300 g); chronic constrictive injury (CCI).

Q0682 Cirillo,G., Bianco,M.R., Colangelo,A.M., Cavaliere,C., Daniele,D., Zaccaro,L., Alberghina,L., Papa,M. Reactive astrocytosis-induced perturbation of synaptic homeostasis is restored by nerve growth factor. NEUROBIOLOGY OF DISEASE 2011; 41(-3-):630-639. >>> Nerve growth factor, beta, recomb.; GM6001; CSF, artificial; albumin, rat serum; CSF/CNS (intrathecal, subarachnoid space); Rat; 2001; 7 days; Controls received mp w/ vehicle; animal info (Sprague-Dawley, male, 250-300 g); enzyme inhibitor (metalloproteinase); PE10 connected to PE60 tubing.

Q0668 Beguin,P.C., El-Helou,V., Gillis,M.A., Duquette,N., Gosselin,H., Brugada,R., Villeneuve,L., Lauzier,D., Tanguay,J.F., Ribuot,C., Calderone,A. Nestin((+)) Stem Cells Independently Contribute to Neural Remodelling of the Ischemic Heart. Journal of Cellular Physiology 2011; 226(-5-):1157-1165. >>> Nerve growth factor, 2.5S; SC; Rat; 2ML1; 1 week; Controls received mp w/ saline; animal info (adult, male, Sprague-Dawley).

Q0544 Hobara,N., Yoshida,N., Goda,M., Yokomizo,A., Kitamura,Y., Sendou,T., Kawasaki,H. Neurotrophic Effect of Hepatic Growth Factor (HGF) on Reinnervation of Perivascular Calcitonin Gene-Related Peptide (CGRP)-Containing Nerves Following Phenol-Induced Nerve Injury in the Rat Mesenteric Artery. JOURNAL OF PHARMACOLOGICAL SCIENCES 2008; 108(-4-):495-504. >>> Hepatic growth factor, human; nerve growth factor; PBS; Triton-X; saline, sterile; IP; Rat; 2001; 7 days; Controls received mp w/ saline; animal info (8 wks old, Wistar).

Q0468 Conner,J.M., Franks,K.M., Titterness,A.K., Russell,K., Merrill,D.A., Christie,B.R., Sejnowski,T.J., Tuszynski,M.H. NGF Is Essential for Hippocampal Plasticity and Learning. Journal of Neuroscience 2009; 29(-35-):10883-10889. >>> Nerve growth factor, recomb. human; CSF, artificial; albumin, rat; CSF/CNS (septum); Rat; 2002; ; Controls received mp w/ vehicle; animal info (adult, female F344, 175-200 g, 3-4 months old); behavioral testing (Morris water maze test).

Q0157 Lazo,O.M., Mauna,J.C., Pissani,C.A., Inestrosa,N.C., Bronfman,F.C. Axotomy-induced neurotrophic withdrawal causes the loss of phenotypic differentiation and downregulation of NGF signalling, but not death of septal cholinergic neurons. Molecular Neurodegeneration 2010; 5(-;-):U1-U12. >>> Nerve growth factor; CSF, artificial; CSF/CNS; Rat; 2ML2; 14 days; Controls received mp w/ vehicle; animal info (Sprague Dawley, 280-300 g.); aCSF recipe; incorrectly stated 2002 pump.

Q0129 Goda,M., Atagi,S., Amitani,K., Hobara,N., Kitamura,Y., Kawasaki,H. Nerve Growth Factor Suppresses Prostate Tumor Growth. JOURNAL OF PHARMACOLOGICAL SCIENCES 2010; 112(-4-):463-466. >>> Nerve growth factor; SC; Mice (nude); 1002; 2 weeks; Controls received mp w/ saline; cancer (prostate); animal info (BALB/c, Slc, 5 wks old, nu/nu).

Q0009 Cirillo,G., Cavaliere,C., Bianco,M.R., De Simone,A., Colangelo,A.M., Sellitti,S., Alberghina,L., Papa,M. Intrathecal NGF Administration Reduces Reactive Astrocytosis and Changes Neurotrophin Receptors Expression Pattern in a Rat Model of Neuropathic Pain. Cellular and Molecular Neurobiology 2010; 30(-1-):51-62. >>> Nerve growth factor, b-, recomb. rat; CSF, artificial; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle; peptides; animal info (adult, male, Sprague-Dawley, 250-300 g); SCI; spinal cord injury; behavioral testing (thermal nociceptive testing, mechanical allodynia).

P9872 Unezaki,S., Yoshii,S., Mabuchi,T., Saito,A., Ito,S. Effects of neurotrophic factors on nerve regeneration monitored by in vivo imaging in thy1-YFP transgenic mice. Journal of Neuroscience Methods 2009; 178(-2-):308-315. >>> Nerve growth factor; glial-derived neurotrophic factor; Saline; CSF/CNS (sciatic nerve); Mice (transgenic); 1004; 4 weeks; Controls received mp w/ vehicle; half-life (p. 308) "short"; animal info (10 wks old, 20 g., Thy1-YEP); image of pump pg. 309; schematic of drug delivery system, fig. 1); "Because of the short biological half-life of neurotrophic factors, a delivery system that protects the protein and slowly releases it locally over a prolonged period of time is required." pg. 308; tissue perfusion (sciatic nerve).

P9539 Xanthos,D.N., Kumar,N., Theodorsson,E., Coderre,T.J. The roles of nerve growth factor and cholecystokinin in the enhancement of morphine analgesia in a rodent model of central nervous system inflammation. Neuropharmacology 2009; 56(-3-):684-691. >>> Nerve growth factor, beta; CSF, artificial; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle; animal info (male, Long Evans, hooded).

P9516 Wissman,A.M., Brenowitz,E.A. The Role of Neurotrophins in the Seasonal-Like Growth of the Avian Song Control System. Journal of Neuroscience 2009; 29(-20-):6461-6471. >>> TrkB-Fc; TrkC-Fc; brain-derived neurotrophic factor; nerve growth factor; PBS; CSF/CNS (robust nucleus of the arcopallium); Bird; 1002; ; Controls received mp w/ vehicle; functionality of mp verified by residual volume; ALZET brain infusion kit 2 used; animal info (sparrow, adult, male, Gambel's white crowned).

P9466 Xing,J.H., Lu,J., Li,J.H. Contribution of nerve growth factor to augmented TRPV1 responses of muscle sensory neurons by femoral artery occlusion. American Journal of Physiology-Heart and Circulatory Physiology 2009; 296(-5-):H1380-H1387. >>> Nerve growth factor; SC; Rat; 1003D; 72 hours; Controls received mp w/ saline to contralateral leg; cardiovascular; peptides; multiple pumps per animal (2); ischemia (muscle); animal info (male, Sprague Dawley, 5-7 wks old); SC in the hindlimb.

P9324 Averill,S., Inglis,J.J., King,V.R., Thompson,S.W.N., Cafferty,W.B.J., Shortland,P.J., Hunt,S.P., Kidd,B.L., Priestley,J.V. Reg-2 expression in dorsal root ganglion neurons after adjuvant-induced monoarthritis. Neuroscience 2008; 155(-4-):1227-1236. >>> Nerve growth factor, recomb. human; glial-derived neurotrophic factor, recomb. human; leukemia inhibitory factor, recomb. human; Saline; albumin, rat serum; CSF/CNS (intrathecal); Rat; 2002; 14 days; Controls received mp w/ vehicle; peptides, animal info (male, Wistar, 220-400 g.).

P9004 Clark,R.S.B., Nathaniel,P.D., Zhang,X.P., Dixon,C.E., Alber,S.M., Watkins,S.C., Melick,J.A., Kochanek,P.M., Graham,S.H. boc-Aspartyl(OMe)-fluoromethylketone attenuates mitochondrial release of cytochrome c and delays brain tissue loss after traumatic brain injury in rats. Journal of Cerebral Blood Flow and Metabolism 2007; 27(-2-):316-326. >>> Nerve growth factor; CSF, artificial; albumin, mouse; CSF/CNS (parietal cortex); Rat; 2002; 14 days; Controls received mp w/ vehicle; no stress (see pg. 321); peptides; cardiovascular; animal info (male, Sprague Dawley, 280-400 g., CCI brain injury); behavioral testing (beam balance, beam walking, Morris water maze).

P8890 Hobara,N., Goda,M., Yoshida,N., Takatori,S., Kitamura,Y., Mio,M., Kawasaki,H. Angiotensin II type 2 receptors facilitate reinnervation of phenol-lesioned vascular calcitonin gene-related peptide-containing nerves in rat mesenteric arteries. Neuroscience 2007; 150(-3-):730-741. >>> Angiotensin II; nerve growth factor; PD123319; losartan; Saline; water; IP; Rat; 2001; 7 days; Controls received mp w/ vehicle; functionality of mp verified by systolic blood pressure; peptides; post op. care (penicillin); animal info (8 wks old, Wistar).

P8576 Villoslada,P., Hauser,S.L., Bartke,I., Unger,J., Heald,N., Rosenberg,D., Cheung,S.W., Mobley,W.C., Fisher,S., Genain,C.P. Human Nerve Growth Factor Protects Common Marmosets against Autoimmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System. Journal of Experimental Medicine 2000; 191(-10-):1799-1806. >>> Saline; nerve growth factor, recomb. human; cytochrome C; CSF/CNS; Marmoset; 2004; 35-42 days; Controls received mp w/ cytochrome C; functionality of mp verified by CSF levels of rhNGF; pumps replaced after 7-14 days of saline; immunology; ALZET brain infusion kit used; peptides; animal info (callithrix jacchus); "we chose to use an intracranial route to ensure accurate delivery of the drug into the CNS. This resulted in sustained elevated concentrations of rhNGF in the CSF of all rhNGF-treated animals." (p. 1801).

P8526 Randolph,C.L., Bierl,M.A., Isaacson,L.G. Regulation of NGF and NT-3 protein expression in peripheral targets by sympathetic input. Brain Research 2007; 1144(--):59-69. >>> Nerve growth factor, mouse; Bisbenzimide; CSF/CNS; Rat; 2002; 2 weeks; Controls received no treatment; peptides; animal info (female, Sprague-Dawley, 3 months old); bisbenzimide (fluorescent marker) added to infusate to monitor cannula placement.

P8426 Hobara,N., Goda,M., Kitamura,Y., Sendou,T., Gomita,Y., Kawasaki,H. Adrenomedullin facilitates reinnervation of phenol-injured perivascular nerves in the rat mesenteric resistance artery. Neuroscience 2007; 144(-2-):721-730. >>> Adrenomedullin, recomb. human; nerve growth factor; Saline, sterile; IP; Rat; 2001; 7 days; Controls received mp w/ vehicle; dose-response (fig. 2); peptides; animal info (Wistar, 8 wk old, perivascular denervation).

P8023 Niewiadomska,G., Baksalerska-Pazera,M., Gasiorowska,A., Mietelska,A. Nerve growth factor differentially affects spatial and recognition memory in aged rats. Neurochemical Research 2006; 31(-12-):1481-1490. >>> Nerve growth factor, beta; CSF, artificial; CSF/CNS; Rat; 2004; 1 month; ALZET brain infusion kit used; post op. care (antibiotic and analgesic to scalp + fluid therapy); silastic tubing used; 28 G cannula.

P7978 Engelhardt,M., Di Cristo,G., Berardi,N., Maffei,L., Wahle,P. Differential effects of NT-4, NGF and BDNF on development of neurochemical architecture and cell size regulation in rat visual cortex during the critical period. European Journal of Neuroscience 2007; 25(-2-):529-540. >>> Nerve growth factor, mouse; NT-4, human recomb.; brain-derived neurotrophic factor, recomb. human; CSF/CNS (visual cortex); Rat; 1007D; 8 days; Post op. care (antibiotics and local anesthetics); animal info (Long-Evans); dental cement used; 30 G cannula used; tissue perfusion (visual cortex).

P7961 Kromer,L.F. Nerve Growth Factor Treatment After Brain Injury Prevents Neuronal Death. Science 1987; 235(-4785-):214-216. >>> Nerve growth factor; cytochrome C; Saline, sterile; CSF/CNS; Rat; 2002; 2 weeks; Controls received mp w/ cytochrome C; functionality of mp verified by residual volume; axotomy; stability verified by ability of residual NGF to promote neurite outgrowth; good methods; peptides; animal info (adult, female, Sprague-Dawley).

P7728 Frielingsdorf,H., Thal,L.J., Pizzo,D.P. The septohippocampal cholinergic system and spatial working memory in the Morris water maze. Behavioural Brain Research 2006; 168(-1-):37-46. >>> Nerve growth factor, recomb. human; CSF, artificial; gentamicin; albumin, rat serum; CSF/CNS; Rat; 2004; 4 weeks; Controls received mp w/ vehicle; functionality of mp verified by residual volume; cannula placement confirmed by cresyl violet staining; peptides; animal info (male, Fisher 344, 13-14 wk. old, medial septum lesion, 400g); mp primed 2 days in 37 Celsius saline.

P7582 Cardoso,A., Paula-Barbosa,M.M., Lukoyanov,N.V. Reduced density of neuropeptide Y neurons in the somatosensory cortex of old male and female rats: Relation to cholinergic depletion and recovery after nerve growth factor treatment. Neuroscience 2006; 137(-3-):937-948. >>> Dye, methylene blue; nerve growth factor; CSF, artificial; BSA; CSF/CNS; Rat; 2002; 14 days; Controls received mp w/ vehicle or sham surgery; functionality of mp verified by pretesting; Alzet brain infusion kit used; post op. care (antiseptic); animal info (male, female, Wistar 6 month old, 24 month old); Lynch coil filled with NGF, air-oil spacer between mp and catheter, mp filled with dye.

P7365 Jakubowska-Dogru,E., Guemuesbas,U. Chronic intracerebroventricular NGF administration improves working memory in young adult memory deficient rats. Neuroscience Letters 2005; 382(-1-2-):45-50. >>> Nerve growth factor, recomb. rat; CSF, artificial; CSF/CNS; Rat; 2004; 28 days; Controls received mp w/ vehicle; memory; behavioral study.

P7289 Pereira,P.A., Cardoso,A., Paula-Barbosa,M.M. Nerve growth factor restores the expression of vasopressin and vasoactive intestinal polypeptide in the suprachiasmatic nucleus of aged rats. Brain Research 2005; 1048(-1-2-):123-130. >>> Nerve growth factor; dye, methylene blue; CSF/CNS; Rat; 2002; 14 days; Functionality of mp verified by pretesting delivery rate; ALZET brain infusion kit used; peptides; post op. care (SC saline, local antiseptic); mp filled with Methylene blue, air-oil spacer at tubing connection, tubing filled with NGF; Lynch coil; "Because there is evidence that the surgical procedure does not interfere with the structure of SCN, vehicle - treated rats were not included in this study." (p. 124).

P7244 Obata,K., Katsura,H., Mizushima,T., Yamanaka,H., Kobayashi,K., Dai,Y., Fukuoka,T., Tokunaga,A., Tominaga,M., Noguchi,K. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. Journal of Clinical Investigation 2005; 115(-9-):2393-2401. >>> SB203580; antibody, anti-nerve growth factor; oligodeoxynucleotide, antisense; oligodeoxynucleotide, FITC antisense; oligodeoxynucleotide, missense; DMSO; saline; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle, or sham surgery or mismatch ODN or contralateral no treatment; antisense (TRPA1); brain tissue distribution; 50% DMSO.

P7008 DeKosky,S.T., Abrahamson,E.E., Taffe,K.M., Dixon,C.E., Kochanek,P.M., Ikonomovic,M.D. Effects of post-injury hypothermia and nerve growth factor infusion on antioxidant enzyme activity in the rat: implications for clinical therapies. Journal of Neurochemistry 2004; 90(-4-):998-1004. >>> Nerve growth factor; CSF, artificial; CSF/CNS; Rat; 2002; 1,3 days; Controls received mp w/ vehicle; stability verified by increased ChAT activity.

P6996 Bruno,M.A., Clarke,P.B.S., Seltzer,A., Quirion,R.M., Burgess,K., Cuello,A.C., Saragovi,H.U. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. Journal of Neuroscience 2004; 24(-37-):8009-8018. >>> Nerve growth factor; D3; dye, methylene blue; CSF, artificial, buffered; saline; CSF/CNS; Rat; 2002; 14 days; Controls received mp w/ vehicle; functionality of mp verified by infusion volume (pg. 8011); no stress (see pg. 8012); ALZET brain infusion kit used; peptides; used air-oil spacer in PE tubing at pump end, PE tubing used in coil for D3 mp filled with dye; D3 is a peptidomimetic which binds TrKA.

P6930 Gillespie,L.N., Clark,G.M., Marzella,P.L. Delayed neurotrophin treatment supports auditory neuron survival in deaf guinea pigs. NeuroReport 2004; 15(-7-):1121-1125. >>> Brain-derived neurotrophic factor; nerve growth factor; NT-3; NT-4/5; Ear (scala tympani, cochlea); Guinea-pig; 2004; 28 days; Tissue perfusion.

P6922 Chen,J.R., Wang,Y.J., Tseng,G.F. The effects of decompression and exogenous NGF on compressed cerebral cortex. Journal of Neurotrauma 2004; 21(-11-):1640-1651. >>> Nerve growth factor; CSF, artificial; CSF/CNS; Rat; 2ML2; 14 days; Used coiled PE tubing (Lynch coil).

P6761 McCallister,W.V., McCallister,E.L., Dubois,B., Trumble,T.E. Regeneration along intact nerves using nerve growth factor and ciliary neurotrophic factor. Journal of Reconstructive Microsurgery 2004; 20(-6-):473-481. >>> Nerve growth factor; ciliary neurotrophic factor; CSF/CNS (peroneal nerve); Rat; 2ML4; 28 days; Controls received mp w/ isotonic saline; peptides; mp primed 24 hours in 37 degrees Celsius saline.

P6706 Paula-Barbosa,M.M., Pereira,P.A., Cadete-Leite,A., Madeira,M.D. NGF and NT-3 exert differential effects on the expression of neuropeptides in the suprachiasmatic nucleus of rats withdrawn from ethanol treatment. Brain Research 2003; 983(-1-2-):64-73. >>> Nerve growth factor; NT-3; CSF, artificial; BSA; CSF/CNS; Rat; 2002; 10 days; Controls received mp w/ vehicle; ALZET brain infusion kit used; dependence; post op. care (local antiseptic); agent was placed in catheter, tubing had an air-oil spacer at pump end, mp contained methylene blue (p.66).

P6679 Castellanos,M.R., Aguiar,J., Fernandez,C.I., Almaguer,W., Mejias,C., Varela,A. Evaluation of the neurorestorative effects of the murine beta-nerve growth factor infusions in old rat with cognitive deficit. Biochemical and Biophysical Research Communications 2003; 312(-4-):867-872. >>> Nerve growth factor, beta, murine; Saline; CSF/CNS (parenchyma); CSF/CNS; Rat; 2002; 2 weeks; Comparison of ICV infusion vs. intraparenchymal infusion.

P6637 Van der Zee,C.E.E.M., Hagg,T. Delayed NGF Infusion Fails to Reverse Axotomy-Induced Degeneration of Basal Forebrain Cholinergic Neurons In Adult P75LNTR-Deficient Mice. Neuroscience 2002; 110(-4-):641-651. >>> Nerve growth factor-beta; CSF/CNS (ipsilateral septum); Mice; 1007D; 7 days; Controls received mp w/ vehicle; peptides.

P6451 Seki,S., Sasaki,K., Igawa,Y., Nishizawa,O., Chancellor,M.B., De Groat,W.C., Yoshimura,N. Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. Journal of Urology 2004; 171(-1-):478-482. >>> Antibody, anti-nerve growth factor; CSF, artificial; CSF/CNS (intrathecal); Rat; 2002; 14 days; Controls received mp w/ vehicle; spinal cord injury; PE-10 used for catheterization.

P6354 Harrington,A.W., Leiner,B., Blechschmitt,C., Arevalo,J.C., Lee,R., Moerl,L., Meyer,M., Hempstead,B.L., Yoon,S.O., Giehl,K.M. Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2004; 101(-16-):6226-6230. >>> Antibody, anti-nerve growth factor, neutralizing mouse; serum; immunoglobulin-G; penicillin; streptomycin; PBS; CSF/CNS (cortex); Rat; 2001; 1 week; Controls received mp w/ vehicle.

top of page

7. Placental Growth Factor

P7114 Carmeliet,P., Moons,L., Luttun,A., Vincenti,V., Compernolle,V., De Mol,M., Wu,Y., Bono,F., Devy,L., Beck,H., Scholz,D., Ackerk,T., DiPalma,T., Dewerchin,M., Noel,A., Stalmans,I., Barra,A., Blacher,S., VandenDriessche,T., Ponten,A., Eriksson,U., Plate,K.H., Foidart,J.M., Schaper,W., Charnock-Jones,S., Hicklin,D.J., Herbert,J.M., Collen,D., Persico,M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Medicine 2001; 7(-5-):575-583. >>> Placental growth factor-1, recomb. human; Mice; 2001; 7 days; Controls received mp w/ vehicle; replacement therapy (PgF -/- mice); cardiovascular; ischemia (retinal); embryology.

P6669 Tamarat,R., Silvestre,J.S., Ricousse-Roussanne,S., Barateau,V., Lecomte-Raclet,L., Clergue,M., Duriez,M., Tobelem,G., Levy,B.I. Impairment in ischemia-induced neovascularization in diabetes - Bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. American Journal of Pathology 2004; 164(-2-):457-466. >>> Placental growth factor; SC; Mice; 2001; 14 days; Diabetes, placenta growth factor (PIGF) is a VEGF homologue; ischemia.

P5978 Luttun,A., Tjwa,M., Moons,L., Wu,Y., Angelillo-Scherrer,A., Liao,F., Nagy,J.A., Hooper,A., Priller,J., De Klerck,B., Compernolle,V., Daci,E., Bohlen,P., Dewerchin,M., Herbert,J.M., Fava,R., Matthys,P., Carmeliet,G., Collen,D., Dvorak,H.F., Hicklin,D.J., Carmeliet,P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Medicine 2002; 8(-8-):831-840. >>> Placental growth factor; vascular endothelial growth factor; SC; Mice; 2001; 7 days; Angiogenesis.

P5645 Pipp,F., Heil,M., Issbrucker,K., Ziegelhoeffer,T., Martin,S., van den Heuvel,J., Weich,H., Fernandez,B., Golomb,G., Carmeliet,P., Schaper,W., Clauss,M. VEGFR-1-selective VEGF homologue PlGF is arteriogenic - Evidence for a monocyte-mediated mechanism. Circulation Research 2003; 92(-4-):378-385. >>> Vascular endothelial growth factor; Vascular endothelial growth factor-E; Monocyte chemoattractant protein-1; Placental growth factor; Phosphate buffer; albumin; IA (femoral); Mice; rabbit; 1 week; Controls received mp w/ vehicle; dose-response (p.381); peptides; placenta growth factor (PlGF) is a VEGF homologue; VEGF-E is a chimera containing the heparin-binding domain of VEGF; MCP-1.

top of page

8. Transforming Growth Factor

P9873 Echeverry,S., Shi,X.Q., Haw,A., Liu,H., Zhang,Z., Zhang,J. Transforming growth factor-beta-1 impairs neuropathic pain through pleiotropic effects. Molecular Pain 2009; 5(-;-):U1-U18. >>> Transforming growth factor-1, beta; CSF/CNS (intrathecal); Rat; 1007D; 2002; 7, 14 days; Animal info (male, Sprague Dawley, 250-275 g.); incorrectly statead pump model as 2002D.

P9848 McGrath,L.J., Ingman,W.V., Robker,R.L., Robertson,S.A. Exogenous transforming growth factor beta1 replacement and fertility in male Tgfb1 null mutant mice. REPRODUCTION FERTILITY AND DEVELOPMENT 2009; 21(-4-):561-570. >>> Transforming growth factor beta-1, recomb. human; BSA; PBS; SC; Mice; 1002; 2 weeks; Controls received mp w/ vehicle; comparios of PO gavage vs. mp; half-life (p. 563) 1 hour; animal info (Tgfb1 null); "continuous supply of rhLTGFB1 by subcutaneous insertion of osmotic pumps successfully increased circulating TGFB1 to detectable levels" pg. 568.

P9807 Guerra-Crespo,M., Gleason,D., Sistos,A., Toosky,T., Solaroglu,I., Zhang,J.H., Bryant,P.J., Fallon,J.H. TRANSFORMING GROWTH FACTOR-ALPHA INDUCES NEUROGENESIS AND BEHAVIORAL IMPROVEMENT IN A CHRONIC STROKE MODEL. Neuroscience 2009; 160(-2-):470-483. >>> Transforming growth factor; CSF/CNS; Rat; 2004; 28 days; Controls received mp w/ PBS; ALZET brain infusion kit used; animal info (90 days old, MCAO); behavioral testing (cylinder corner test).

P9772 Cooper,O., Isacson,O. Intrastriatal Transforming Growth Factor Delivery to a Model of Parkinson's Disease Induces Proliferation and Migration of Endogenous Adult Neural Progenitor Cells without Differentiation into Dopaminergic Neurons. The Journal of Neuroscience 2004; 24(-41-):8924-8931. >>> Transforming growth factor, alpha; PBS; CSF/CNS (striatum); Rat; 2004; 1, 2, 4 weeks; Controls received mp w/ vehicle; ALZET brain infusion kit 2 used; animal info (naive, adult, male, Sprague Dawley); neurodegenerative (Parkinson's Disease); brain tissue distribution; tissue perfusion (striatum).

P9532 Dufour,C., Holy,X. Transforming growth factor-beta prevents osteoblast apoptosis induced by skeletal unloading via PI3K/Akt, Bcl-2, and phospho-Bad signaling. J Physiol Endocrinol Metab 2008; (-294-):E794-E801. >>> Transforming growth factor-beta2; Rat; 2, 4, 7 days; Animal info (adult, 4 wks old, Wistar, 130g.).

P9402 de Chevigny,A., Cooper,O., Vinuela,A., Reske-Nielsen,C., Lagace,D.C., Eisch,A.J., Isacson,O. Fate mapping and lineage analyses demonstrate the production of a large number of striatal neuroblasts after transforming growth factor alpha and noggin striatal infusions into the dopamine-depleted striatum. Stem Cells 2008; 26(-9-):2349-2360. >>> Transforming growth factor-a; noggin; PBS; CSF/CNS (striatum); Rat; 1002; 2004; 14, 28, 41 days; Controls received mp w/ vehicle; ALZET brain infusion kit 2 used; brain tissue distribution; peptides; animal info (female, Sprague Dawley, 250-300 g.); behavioral testing (rotation behavior); noggin is a bone morphogenetic protein antagonist; neurodegenerative (Parkinson's Disease).

P9315 Gleason,D., Fallon,J.H., Guerra,M., Liu,J.C., Bryant,P.J. Ependymal stem cells divide asymmetrically and transfer progeny into the subventricular zone when activated by injury. Neuroscience 2008; 156(-1-):81-88. >>> Transforming growth factor-a; PBS; CSF/CNS (caudate putamen); Rat; 1, 3, 5, 7, 28 days; Peptides, animal info (male, 10 wks old); neurodegenerative (Parkinson's Disease); neural stem cell research.

P9186 White,R.E., Yin,F.Q., Jakeman,L.B. TGF-alpha increases astrocyte invasion and promotes axonal growth into the lesion following spinal cord injury in mice. Experimental Neurology 2008; 214(-1-):10-24. >>> Transforming growth factor-alpha; Serum, mouse; PBS; CSF/CNS (intrathecal); Mice; 2002; 14 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; post op. care (Baytril); animal info (female, adult, C57BL/6, 10 wks old, 17-20 g.); spinal cord injury; pumps were primed in saline at 37 degree Celsius for 24 hours; pumps were weighed before and after filling; good methods.

P8988 Wachs,F.P., Winner,B., Couillard-Despres,S., Schiller,T., Aigner,R., Winkler,J., Bogdahn,U., Aigner,L. Transforming growth factor-beta 1 is a negative modulator of adult neurogenesis. Journal of Neuropathology and Experimental Neurology 2006; 65(-4-):358-370. >>> Transforming growth factor-B1, recomb.; CSF, artificial; CSF/CNS; Rat; 2002; 7 days; Controls received mp w/ vehicle; peptides; animal info (female, Fischer-344, 2-3 months old, 180 g.).

P7353 Snodgrass-Belt,P., Gilbert,J.L., Davis,F.C. Central administration of transforming growth factor-alpha and neuregulin-1 suppress active behaviors and cause weight loss in hamsters. Brain Research 2005; 1038(-2-):171-182. >>> Transforming growth factor-alpha; BSA; acetic acid; CSF, artificial; CSF/CNS (third ventricle); Hamster; 2002; 16-20 days; Circadian; plastics one cannula; cannula/tubing were filled with aCSF to allow for a 48 delay; behavioral study.

P7136 Bandyopadhyay,A., Wang,L., Loepz-Casillas,F., Mendoza,V., Yeh,I.T., Sun,L.Z. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. PROSTATE 2005; 63(-1-):81-90. >>> Transforming growth factor-B3 receptor, recomb. soluble; PBS; SC; Mice (nude); 2002; 14 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; no stress (see pg. 84,88); cancer (prostate); multiple pumps per animal (2).

P7068 Harris-White,M.E., Balverde,Z., Lim,G.P., Kim,P., Miller,S.A., Hammer,H. Role of LRP in TGFbeta2-mediated neuronal uptake of A beta and effects on memory. Journal of Neuroscience Research 2004; 77(-2-):217-228. >>> Amyloid protein, beta; transforming growth factor-B2; receptor-associated protein; HEPES buffer; CSF/CNS; Mice; 1002; 2 weeks; Controls received mp w/ vehicle; stability verified by incubation at 37 degree Celsius for 2,4 weeks; peptides; RAP is a LRP (lipoprotein receptor-related protein) antagonist; memory.

P6364 Gregg,C., Weiss,S. Generation of functional radial glial cells by embryonic and adult forebrain neural stem cells. Journal of Neuroscience 2003; 23(-37-):11587-11601. >>> Fibroblast growth factor-2; epidermal growth factor; transforming growth factor; Saline; serum albumin; CSF/CNS; Mice; 1007D; 6,12 days; Pumps replaced at day 7 for 12 d EGF infusions.

P6205 Guo,H.L., Epperly,M.W., Bernarding,M., Nie,S.H., Gretton,J., Jefferson,M., Greenberger,J.S. Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) intratracheal gene therapy reduction of irradiation-induced inflammatory cytokines does not protect orthotopic Lewis Lung Carcinomas. In Vivo 2003; 17(-1-):13-21. >>> Tumor necrosis factor-alpha; transforming growth factor-beta; interleukin-1; Saline, normal; SC; Mice; 1007D; 7 days; Controls received mp w/ vehicle; no stress (see pg. 17); cancer (lung).

P6033 Boengler,K., Pipp,F., Fernandez,B., Ziegelhoeffer,T., Schaper,W., Deindl,E. Arteriogenesis is associated with an induction of the cardiac ankyrin repeat protein (carp). Cardiovascular Research 2003; 59(-3-):573-581. >>> Monocyte chemoattractant protein-1; doxorubicin; transforming growth factor-B1; IA (femoral); Rabbit; 2ML1; 24 hours; Cardiovascular.

P5729 Boengler,K., Pipp,F., Fernandez,B., Richter,A., Schaper,W., Deindl,E. The ankyrin repeat containing SOCS box protein 5: a novel protein associated with arteriogenesis. Biochemical and Biophysical Research Communications 2003; 302(-1-):17-22. >>> Monocyte chemoattractant protein-1; Transforming Growth Factor-B; Doxorubicin; IA (femoral); Rabbit; 2ML1; 24 hours; Cardiovascular; peptides; MCP-1 is monocyte chemoattractant protein 1.

P5149 Nakazato,F., Tada,T., Sekiguchi,Y., Murakami,K., Yanagisawa,S., Tanaka,Y., Hongo,K. Disturbed spatial learning of rats after intraventricular administration of transforming growth factor-beta 1. NEUROLOGIA MEDICO-CHIRURGICA 2002; 42(--):151-157. >>> Transforming Growth Factor-B2, soluble receptor; Polymyxin B; IP; mice; 1007D; 2002; ; Arthritis; controls received empty pumps or mp w/ vehicle; functionality of mp verified by residual aspiration; pumps replaced after 14 days; stability verified by ELISA after infusion (p. 508, 510); soluble TGF-B RII selectively inhibits transforming growth factor-B; peptides; polymyxin B included as endotoxin inhibitor; 2002 pumps used for 7 and 14 day administration, 21-day group received a 1007D pump for final 7 days.

P5015 Kramer,A., Yang,F.C., Snodgrass,P., Li,X., Scammell,T.E., Davis,F.C., Weitz,C.J. Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. Science 2001/12/21; 294(-5551-):2511-2515. >>> Transforming growth factor-a; Brain-derived neurotrophic factor; Vasoactive intestinal polypeptide; Peptide, histidine-isoleucine; Gastrin releasing peptide; Substance P; Neuromedin-C; Neurokinin A; Neuropeptide K; Neuropeptide Y; Somatostatin; Antrin; Cholecystokinin; Thyrotropin-releasing hormone; Neurotensin; Neuromedin N;; CSF, artificial; CSF/CNS (third ventricle); hamster; 2002; 18-22 days; peptides.

P4999 Tamada,H., Sakaguchi,H., Inaba,T., Kawate,N., Sawada,T. The effect of transforming growth factor-alpha on the progression of decidualization in rats. LIFE SCIENCES 2001; 69(--):1549-1558. >>> Transforming growth factor-a; PB1 medium; Intrauterine; rat; 2001; 2 days; controls received mp w/ vehicle; tissue perfusion (uterine horn lumen); TGF-a was recombinnant human.

P4838 Goodman,S., Song,Y., Chun,L., Aspenberg,P., Plouhar,P., Glancy,T., Regula,D., Smith,R.L. Effects of local infusion of TGFb on bone ingrowth in rabbit chambers.. Journal of Biomedical Materials Research 2000; 53(--):475-479. >>> Transforming growth factor-B1;; Gelatin; Sodium acetate;; Bone (tibia);; rabbit;; 2001D; 2001;; 1 week; 1 day;; Peptides; growth factor treatment consisted of 1 day infusion with 2001D pumps or 1 week infusion with 2001 pumps, followed by carrier infusion for 3 weeks; carrier solution consisted of 1% gelatin, 20 mm sodium acetate; TGF infusion into drug test chamber implanted in the tibia;.

P4780 Dillard,D.G., Gal,A.A., Roman-Rodriguez,J., White,S., Jacobs,I.N. Transforming growth factor and neutralizing antibodies in subglottic stenosis.. Annals of Otology Rhinology and Laryngology 2001; 110(--):393-400. >>> Transforming growth factor-B1; Antibody, anti-human TGF-B1;; PBS; BSA;; Larynx;; rat;; 1, 7, 21 days;; Controls received mp w/ vehicle; immunology; peptides; special delivery device attached to pump, p. 394; wound healing study;.

P4770 Rauch,F., Lauzier,D., Travers,R., Glorieux,F., Hamdy,R. Effects of locally applied transforming growth factor-b1 on distraction osteogenesis in a rabbit limb-lengthening model.. Bone 2000; 26(--):619-624. >>> Transforming growth factor-B1; Bone (tibia); Rabbit; 2ML4; 3 weeks; Controls received mp w/ vehicle; tissue perfusion (osteotomy site via catheter); functionality of mp verified by aspirate residual volume after pump removal; no stress (see pg. 620); stability verified by fibroblast cell growth compared w/ fresh solution 7, 14, 21; peptides; dosage of TGF-b1 was 0, 10, 20, or 40 mg/day; delayed drug delivery for 7 days;.

P4749 Fallon,J, Reid,S, Kinyamu,R, Opole,I, Opole,R, Baratta,J, Korc,M, Endo,T.L, Duong,A, Nguyen,G, Karkehabadhi,M, Twardzik,D, Loughlin,S. In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain.. PNAS 2000; 97(-26-):14686-14691. >>> Transforming growth factor-a;; CSF, artificial;; CSF/CNS (striatum);; rat;; 2002; 2004;; 14, 28 days;; Controls received mp w/ vehicle; good methods priming (p. 14686-87); ALZET brain infusion kit used; peptides; neurodegenerative (Parkinson's disease).

P4739 Kopke,R.D, Jackson,R.L, Li,G, Rasmussen,M.D, Hoffer,M.E, Frenz,D.A, Costello,M, Schultheiss,P, Van De Water,T.R. Growth factor treatment enhances vestibular hair cell renewal and results in improved vestibular function.. PNAS 2001; 98(-10-):5886-5891. >>> Transforming growth factor; insulin-like growth factor I; retinoic acid; brain-derived neurotrophic factor;; PBS; BSA;; Ear (vestibule); Guinea-pig; 2002; 4 weeks; Controls received mp w/ vehicle; pumps replaced after 2 weeks; peptides; IntraEAR catheter used; GFI group pumps filled with TGF, IGF and Retinoic acid; GFII group pumps filled with TGF, IGF, BDNF and retinoic acid; tissue perfusion (vestibule).

P4574 Kurek,J.B, Bower,J.J, White,J.D., Muldoon,C.M, Austin,L. Leukaemia inhibitory factor and other cytokines as factors influencing regeneration of skeletal muscle.. Basic Appl.Myol 1998; 8(-5-):347-360. >>> Leukemia inhibitory factor; Interleukin-6; Transforming growth factor-a;; PBS;; IM;; mice;; 7 days;; controls received mp w/vehicle; tissue perfusion (vastus lateralis muscle); peptides; targeted delivery of growth factors to the site of muscle injury via a cannula; "drug delivery targeted to a discrete tissue or organ offers signicant advantages over systemic administration". (p. 355).

P4254 Wilson,H.M., Minto,A.W.M., Brown,P.A.J., Erwig,L.P., Rees,A.J. Transforming growth factor-beta isoforms and glomerular injury in nephrotoxic nephritis. Kidney International 2000; 57(--):2434-2444. >>> Transforming growth factor-B3, recombinant; Saline; SC; rat; 2001; 7 days; controls received mp w/ vehicle; immunology; peptides; nephritis.

P4130 Roelofs,M., Faggian,L., Pampinella,F., Paulon,T., Franch,R., Chiavegato,A., Sartore,S. Transforming growth factor b1 involvement in the conversion of fibroblasts to smooth muscle cells in the rabbit bladder serosa. Histochemical J. 1998; 30(--):393-404. >>> Transforming growth factor-B1; Epidermal growth factor; Fibroblast growth factor, basic; Colony-stimulating factor, G; Platelet-derived growth factor; Colony-stimulating factor, GM; PBS; bladder wall; rabbit; 2ML2; 2ML4; no duration posted; controls received mp w/PBS; no stress (see pg. 395); "a minipump filled with Evans Blue solution was used to determine area of growth factor delivery"; peptides; tissue perfusion (bladder wall).

P4127 Kuntz,A.L., Oesterle,E.C. Transforming growth factor-a with insulin induces proliferation in rat utricular extrasensory epithelia. Otolaryngol Head Neck Surg 1998; 118(--):816-824. >>> Thymidine; Transforming growth factor-a; Insulin; 3H tracer; Radio-isotopes; ear (cochlea); rat; 1003D; 2001; 3,7 days; controls received mp w/vehicle; tissue perfusion (cochlea); agents infused singly or concomitantly in same pump; ALZET brain infusion kit 1 was modified for cochlear infusion; peptides.

P3965 Gelman,J., Garban,H., Shen,R., Ng,C., Cai,L., Rajfer,J., Ganzalez-Cadavid,N.F. Transforming growth factor-B1 (TGF-B1) in penile and prostate growth in the rat during sexual maturation. J.Androl. 1998; 19(-1-):50-57. >>> Transforming growth factor-B1; Saline; Acetate, sodium; Albumin, bovine serum; penis (corpora cavernosa); rat; 1003D; 7 days; controls received mp w/saline; pumps replaced after 3 days; peptides; recomb. human TGF used.

P3266 Zhou,H., Choong,P.C., Kartsogiannis,V., Martin,T.J., Ng,K.W. Transforming growth factor B1 stimulates bone formation and resorption in an in-vivo model in rabbits. Bone 1995; 17(-4 Supp-):443S-448S. >>> Transforming growth factor-B1; HCl; BSA; bone (tibia); rabbit; 2002; 2,3,4,6 weeks; contralateral controls received vehicle; tissue perfusion (bone implant chamber); silicone tubing used; peptides; recomb. human TGF-B1 used; long-term study; good diagram of pump and experimental system (p. 444S).

P3256 Craig,C.G., Tropepe,V., Morshead,C.M., Reynolds,B.A., Weiss,S., van der Kooy,D. In vivo growth factor expansion of endogenous subependymal neural precursor cell populations in the adult mouse brain. J.Neurosci. 1996; 16(-8-):2649-2658. >>> Epidermal growth factor; Transforming growth factor-a; Fibroblast growth factor; Nerve growth factor; Saline; Albumin, mouse serum; CSF/CNS; mice; 1007D; 6 days; controls received no pumps or mp w/vehicle; peptides; mouse EGF used; human recomb. basic FGF used; mouse 7S NGF used; human recomb. TGF-alpha used.

P3215 Kukreja,S.C., Rosol,T.J., D'Anza,J.J., Wimbiscus,S.A. Effect of transforming growth factor alpha, parathyroid hormone-related protein, or their combination on bone histomorphometry. Bone and Mineral 1993; 23(--):105-111. >>> Transforming growth factor-a; Parathyroid hormone-related peptide (1-34); Acetic acid; Saline; Cysteine; Albumin, bovine serum; mice; 2001; 6 days; controls received mp with vehicle; functionality of mp verified; peptides; peptides given singly and concomitantly; some animals received 2 mps; recomb. human TGF-a used.

P3210 Kihara,A., Pastan,I. Small chimeric toxins containing only transforming growth factor a and domain III of pseudomonas exotoxin with good antitumor activity in mice. Cancer Res. 1994; 54(--):5154-5159. >>> Toxin, transforming growth factor-a chimeric-; PBS; Albumin, human serum; IP; mice (nude); 7 days; controls received mp with PBS; stability of TGFa chimeric toxins found to be 80-100% after 7 days at 37 degrees; cancer.

P2590 Arteaga,C.L., Hurd,S.D., Dugger,T.C., Winnier,A.R., Robertson,J.B. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor a-Pseudomonas exotoxin 40 fusion protein. Cancer Res. 1994; 54(--):4703-4709. >>> Transforming growth factor-a-dcys-PE40; IP; mice (nude); 7 days; controls received mp w/ PBS; stability assessed; 50% cytotoxic potency lost by day 8; cancer; toxicology; peptides; TGF-a-dcys-PE40 used.

P2583 Phillips,P.C., Levow,C., Catterall,M., Colvin,O.M., Pastan,I., Brem,H. Transforming growth factor-a--Pseudomonas exotoxin fusion protein (TGF-a-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res. 1994; 54(--):1008-1015. >>> Transforming growth factor-a-PE38; Albumin, human serum; Sodium chloride; IP; mice (nude); 7 days; comparison of intracranial injections vs. mp; 7 day stability at 37 degrees verified previously; good methods (pg. 1014(45)); TGF-a-PE38 used; cancer.

P2529 Yoshikawa,M., Matsui,Y., Matsumura,K., Nakatani,T., Yamao,J., Kuriyama,S., Ishizaka,S., Fukui,H., Tsujii,T. Effects of continuous intrahepatic administration of transforming growth factor-beta on immunoglobulin production. Int.Hepatol.Commun. 1995; 3(--):116-120. >>> Transforming growth factor-B; HCl; Albumin, bovine serum; PBS; IP; intrahepatic; mice; 2001; 7 days; controls received mp w/ vehicle; tissue perfusion (liver); immunology; peptides; catheter placed in left lobe of liver for intrahepatic delivery; TGF-B used.

P2528 Raju,G.P., Belland,S.E., Eisen,H.J. Prolongation of cardiac allograft survival with transforming growth factor-B1 in rats. Transplantation 1994; 58(-3-):392-396. >>> Transforming growth factor-B1; HCl; Tween 80; IP; rat; 2002; no duration posted; controls received mp w/ vehicle; immunology; peptides; recomb. human TGF-B1 used.

P2191 Desmouliere,A., Geinoz,A., Gabbiani,A., Gabbiani,G. Transforming growth factor-B1 induces a-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J.Cell Biol. 1993; 122(-1-):103-111. >>> Transforming growth factor-B1; Tumor necrosis factor-a; Saline; SC; rat; 2001; 7 days; controls received mp w/saline; functionality of mp verified upon removal; peptides; recomb. human TGF-B1 used; recomb. murine TNF used.

P2058 Ogawa,Y., Ksander,G.A., Pratt,B.M., Sawamura,S.J., Ziman,J.M., Gerhardt,C.O., Avis,P.D., Murray,M.J., McPherson,J.M. Differences in the biological activities of transforming growth factor-B and platelet-derived growth factor. Growth Factors 1991; 5(--):57-68. >>> Transforming growth factor-B1; Platelet-derived growth factor; Albumin; PBS; CSF/CNS (intrathecal, lumbar); guinea-pig; 2001; 8 weeks; stress/adverse reaction: encapsulation (p. 60); peptides; TGF-B1 used.

P1835 Pai,L.H., Gallo,M.G., FitzGerald,D.J., Pastan,I. Antitumor activity of a transforming growth factor a-pseudomonas exotoxin fusion protein (TGF-a-PE40). Cancer Res. 1991; 51(--):2808-2812. >>> Transforming growth factor-a-PE40; Albumin, human serum; PBS; IP; mice; no duration posted; functionality of mp verified by serum TGF-a-PE40 levels; stability measured for 7 days at 37 degrees celsius in vitro; LD50, TGF-a-PE40 has very short half-life of 10-20 min; cancer.

P1812 Martikainen,P., Kyprianou,N., Isaacs,J.T. Effect of transforming growth factor-B1 on proliferation and death of rat prostatic cells. Endocrinology 1990; 127(-6-):2963-2968. >>> Transforming growth factor-B1; Albumin, rat serum; Serum, hypothyroid rat; prostate; 2001; 7 days; tissue perfusion (prostate); porcine TGF-beta1 used.

top of page

9. Transforming Growth Factor

Q0790 Leker,R.R., Toth,Z.E., Shahar,T., Cassiani-Ingoni,R., Szalayova,I., Key,S., Bratincsak,A., Mezey,E. TRANSFORMING GROWTH FACTOR alpha INDUCES ANGIOGENESIS AND NEUROGENESIS FOLLOWING STROKE. Neuroscience 2009; 163(-1-):233-243. >>> Transforming growth factor, alpha; CSF, artificial; CSF/CNS (infarct border); Mice; 1002; 14 days; Controls received mp w/ vehicle; animal info (C57B, male, 4-6 wks old).

P9532 Dufour,C., Holy,X., Marie,P.J. Transforming growth factor-beta prevents osteoblast apoptosis induced by skeletal unloading via PI3K/Akt, Bcl-2, and phospho-Bad signaling. J Physiol Endocrinol Metab 2008; (-294-):E794-E801. >>> Transforming growth factor-beta 2; Rat; 2, 4, 7 days; Animal info (adult, 4 wks old, Wistar, 130g.).

top of page

10. Vascular Endothelial Growth Factor

Q0878 Ortuzar,N., Argandona,E.G., Bengoetxea,H., Lafuente,J.V. Combination of intracortically administered VEGF and environmental enrichment enhances brain protection in developing rats. Journal of Neural Transmission 2011; 118(-1-):135-144. >>> Vascular endothelial growth factor; CSF/CNS (cortex); Rat; 1007D; 7 days; Controls received mp w/ PBS or no implantation; animal info (Long-Evans, P18); cyanoacrylate adhesive; ALZET brain infusion kit 3 used; "Total operating time was approximately 25 min." pg 137.

Q0354 Ahmed,A., Singh,J., Khan,Y., Seshan,S.V., Girardi,G. A New Mouse Model to Explore Therapies for Preeclampsia. PLoS One 2010; 5(-10-):U325-U333. >>> Vascular endothelial growth factor (121); PBS, sterile; SC; Mice; 7 days; Animal info (CBA/J x DBA/2 and CBA/J x BALB/c).

Q0400 Bogaert,E., Van Damme,P., Poesen,K., Dhondt,J., Hersmus,N., Kiraly,D., Scheveneels,W., Robberecht,W., Van den Bosch,L. VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. NEUROBIOLOGY OF AGING 2010; 31(-12-):2185-2191. >>> Vascular endothelial growth factor; CSF/CNS; Rat; 2004; 1 week; Controls received mp w/ vehicle; animal info (80 days old).

Q0712 Nicoletti,J.N., Lenzer,J., Salerni,E.A., Shah,S.K., Elkady,A., Khalid,S., Quinteros,D., Rotella,F., Betancourth,D., Croll,S.D. Vascular endothelial growth factor attenuates status epilepticus-induced behavioral impairments in rats. EPILEPSY&BEHAVIOR 2010; 19(-3-):272-277. >>> Vascular endothelial growth factor, 165, recomb. human; vascular endothelial growth factor, inactivated; PBS, sterile; CSF/CNS (hippocampus); Rat; 2002; 2 weeks; Controls received no surgical manipulations or protein infusions; animal info (male Sprague-Dawley, 250-350 g); behavioral testing (Morris water maze, Grid locomotor activity, Light-dark exploration).

Q0514 Lee,C., Agoston,D.V. Inhibition of VEGF receptor 2 increased cell death of dentate hilar neurons after traumatic brain injury. Experimental Neurology 2009; 220(-2-):400-403. >>> Vascular endothelial growth factor (164); SU5416; CSF, artificial; DMSO; CSF/CNS; Rat; 1002; 13 days; Controls received mp w/ vehicle; animal info (young, male, Sprague Dawley, 270-330 g.); cannula placement verified by histology; 1% DMSO used; artificial CSF recipe.

P9814 Santulli,G., Ciccarelli,M., Palumbo,G., Campanile,A., Galasso,G., Ziaco,B., Altobelli,G.G., Cimini,V., Piscione,F., D'Andrea,L.D., Pedone,C., Trimarco,B., Iaccarino,G. In vivo properties of the proangiogenic peptide QK. Journal of Translational Medicine 2009; 7(-;-):U1-U10. >>> Vascular endothelial growth factor-15; vascular endothelial growth factor-165; QK; IA (femoral); Rat; 2002; 14 days; Peptides; animal info (12 wks old, WKY, normosensitive); QK is a de novo engineered VEGF mimicking peptide.

Q0282 Schmidt,C., Bezuidenhout,D., Beck,M., Van der Merwe,E., Zilla,P., Davies,N. Rapid three-dimensional quantification of VEGF-induced scaffold neovascularisation by microcomputed tomography. Biomaterials 2009; 30(-30-):5959-5968. >>> Vascular endothelial growth factor (165); SC; Rat; 1002; 10 days; Controls received mp w/ PBS; animal info (male, Wistar, 234-254 g); functionality of mp verified by residual volume; post op. care (buprenorphine); pump connected to a porous polyurethane construct, schematic on Figure 1A;.

P9708 Schmidt,N.O., Koeder,D., Messing,M., Mueller,F.J., Aboody,K.S., Kim,S.U., Black,P.M., Carroll,R.S., Westphal,M., Lamszus,K. Vascular endothelial growth factor-stimulated cerebral microvascular endothelial cells mediate the recruitment of neural stem cells to the neurovascular niche. Brain Research 2009; 1268(-;-):24-37. >>> Vascular endothelial growth factor, recomb. human; CSF/CNS (parenchyma); Mice (nude); 2004; ; Controls received mp w/PBS; animal info (6 wks old).

P8833 Boodhwani,M., Voisine,P., Rue,M., Sodha,N.R., Feng,J., Xu,S.H., Bianchi,C., Settke,F.W. Comparison of vascular endothelial growth factor and fibroblast growth factor-2 in a swine model of endothelial dysfunction. European Journal of Cardio-thoracic Surgery 2008; 33(-4-):645-650. >>> Vascular endothelial growth factor 165, recomb. human; Heparin; Intramyocardial; Pig (miniswine); 2ML4; 4 weeks; Tissue perfusion (myocardial); half-life (p. 649) "short"; cardiovascular; peptides; ischemia (cardiac); animal info (Yucatan mini-swine, 20-30 kg.).

P9139 Nicoletti,J.N., Shah,S.K., McCloskey,D.P., Goodman,J.H., Elkady,A., Atassi,H., Hylton,D., Rudge,J.S., Scharfman,H.E., Croll,S.D. Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus. Neuroscience 2008; 151(-1-):232-241. >>> Vascular endothelial growth factor, recomb. human; BowAng1; Flt-Fc; CSF/CNS (dorsal hippocampus); Rat; 5 days; Controls received mp w/ PBS; animal info (male, Sprague Dawley, adult, 250-350 g.); cannula, polyvinyl catheter from Plastics One used; BowAng1 is a fusion of four molecules of angiopoietin-1 with two molecules of hFC; Flt-Fc is an immunoadhesin.

P9248 Poesen,K., Lambrechts,D., Van Damme,P., Dhondt,J., Bender,F., Frank,N., Bogaert,E., Claes,B., Heylen,L., Verheyen,A., Raes,K., Tjwa,M., Eriksson,U., Shibuya,M., Nuydens,R., Van den Bosch,L., Meert,T., D'Hooge,R., Sendtner,M., Robberecht,W., Carmeliet,P. Novel Role for Vascular Endothelial Growth Factor (VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration. Journal of Neuroscience 2008; 28(-42-):10451-10459. >>> Vascular endothelial growth factor-B186, recomb. mouse; CSF, artificial; CSF/CNS; Rat; 2004; 100 days; Controls received mp w/ vehicle; long-term study; pumps replaced every 25 days; no stress (see pg. 10456); stability verified by 4 weeks in mp at 37 degrees Celsius; animal info (HAN-Wistar x Sprague Dawley-hSOD1G93A, 60 days old); behavioral testing (Rotarod test); "this delivery route was chosen because previous studies demonstrated that intracerebroventricularly delivered VEGF diffuses from the CSF into the neural parenchyma, where it reaches it's target motor neurons." (p. 10456).

P9198 Rennel,E.S., Hamdollah-Zadeh,M.A., Wheatley,E.R., Magnussen,A., Schueler,Y., Kelly,S.P., Finucane,C., Ellison,D., Cebe-Suarez,S., Ballmer-Hofer,K., Mather,S., Stewart,L., Bates,D.O., Harper,S.J. Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. European Journal of Cancer 2008; 44(-13-):1883-1894. >>> Vascular endothelial growth factor-165-b, recomb.; NaCl, sterile; SC; Mice; 28 days; No stress (see pg. 1888); half-life (p. 1893) 25 min in mice, 13.8-72 min in rats; cancer (colon); post op. care (Temgesic); animal info (C57/Bl6, 720 g.); silk sutures used; "no adverse effects were observed with this infusion of VEGF165b" pg. 1888; compound is an anti angiogenic isoform of VEGF.

P9443 Segi-Nishida,E., Warner-Schmidt,J.L., Duman,R.S. Electroconvulsive seizure and VEGF increase the proliferation of neural stem-like cells in rat hippocampus. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2008; 105(-32-):11352-11357. >>> Vascular endothelial growth factor 164, recomb. rat; PBS; CSF/CNS; Rat; 1003D; 3 days; 24 hours; Controls received mp w/ vehicle; brain tissue distribution; peptides; animal info (male, Sprague Dawley, 175-200 g.); delayed delivery (in the 48 hour infusion, PBS infused for 24 hours to "avoid the influence of cannulation and anesthesia." (p. 11354) then VEGF infused for 24 hours).

P8799 Tsuchiya,A., Heike,T., Baba,S., Fujino,H., Umeda,K., Matsuda,Y., Nomoto,M., Ichida,T., Aoyagi,Y., Nakahata,T. Sca-1+ endothelial cells (SPECs) reside in the portal area of the liver and contribute to rapid recovery from acute liver disease. Biochemical and Biophysical Research Communications 2008; 365(-3-):595-601. >>> Vascular endothelial growth factor-inhibitor; DMSO; IP; Mice; 9, 11 days; Controls received mp w/ vehicle; animal info (C57BL/6; 4, 8, 12 wks old; anti-Fas Ab-induced liver damage); agent also known as CBO-P11.

P8299 Cruze,C.A., Su,F., Limberg,B.J., Deutsch,A.J., Stoffolano,P.J., Dai,H.J., Buchanan,D.D., Yang,H.T., Terjung,R.L., Spruell,R.D., Mittelstadt,S.W., Rosenbaum,J.S. The Y2 receptor mediates increases in collateral-dependent blood flow in a model of peripheral arterial insufficiency. Peptides 2007; 28(-2-):269-280. >>> Peptide YY, recomb. human; peptide YY (3-36), recomb. human; vascular endothelial growth factor 165; PBS; glycerol; sodium citrate; Tween 20; IA (iliac); Rat; 14 days; Controls received mp w/ vehicle; replacement therapy (femoral artery occlusion); dose-response (fig. 4); half-lfie (p. 276)<30 minutes; cardiovascular; peptides; ischemia (hindlimb); animal info (male, Sprague-Dawley, 325-350 grams).

P8366 Dorrell,M.I., Aguilar,E., Scheppke,L., Barnett,F.H., Friedlander,M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2007; 104(-3-):967-972. >>> Vascular endothelial growth factor, aptamer; EMD472523; T2-TrpRS; PBS; CSF/CNS (intratumoral); Rat; 2001D; 2ML2; 2ML4; 3,6 days; 24 hours; Controls received mp w/ vehicle; cancer (gliosarcoma); animal info (male, Fischer, 344); EMD472523 is an integrin antagonist, VEGF aptamer is chemically identical to Macugen; T2 is a proteolytic fragment of tryptophan tRNA synthetase; all agents have angiostatic activity; tissue perfusion (tumor).

R0246 Hedlund,E., Hefferan,M.P., Marsala,M., Isacson,O. Cell therapy and stem cells in animal models of motor neuron disorders. European Journal of Neuroscience 2007; 26(-7-):1721-1737. >>> Vascular endothelial growth factor; CSF/CNS; Rat; ; Animal info (SOD1G93A, P60, P85); neurogenerative (ALS); Review; see p. 1722-1724, 1726-1727; ref. Storkebaum et al, 2005.

P8512 Huang,Y., Chen,X., Dikov,M.M., Novitskiy,S.V., Mosse,C.A., Yang,L., Carbone,D.P. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110(-2-):624-. >>> Vascular endothelial growth factor 165, recomb. human; vascular endothelial growth factor, receptor-2 selective; vascular endothelial growth factor, receptor-1 selective; Mice; 2004; 28 days; Controls received mp w/ PBS; cancer; peptides; animal info (female, Balb/c, 6-8 weeks old); angiogenesis; hematology.

P8306 Tiranathanagul,K., Dhawan,V., Lytle,I.F., Zhang,W., Borschel,G.H., Buffington,D.A., Tziampazis,E., Brown,D.L., Humes,H.D. Tissue engineering of an implantable bioartificial hemofilter. ASAIO Journal 2007; 53(-2-):176-186. >>> Platelet-derived growth factor-BB; vascular endothelial growth factor 164; Saline, normal; albumin, rat serum; acetic acid; IA (femoral); IV (femoral); Rat; 2004; 28 days; Artificial kidney; controls received mp w/ vehicle; peptides; animal info (male, Fisher 344); mp attached by cannula to bioartificial hemofilter device, which surrounded and delivered agent to the femoral vessels; nephrology.

P8267 Warner-Schmidt,J.L., Duman,R.S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2007; 104(-11-):4647-4652. >>> Vascular endothelial growth Factor 164, recomb. rat; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; peptides; animal info (male, Sprague-Dawley, 175-200g.).

P8163 Boodhwani,M., Mieno,S., Voisine,P., Feng,J., Sodha,N., Li,J., Sellke,F.W. High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine. Journal of Thoracic and Cardiovascular Surgery 2006; 132(-6-):1299-1306. >>> Vascular endothelial growth factor 165, recomb. human; Heparin; Perivascular (circumflex coronary artery); Mini-pig; 2ML4; 4 weeks; Cardiovascular; peptides; ischemia (cardiac); animal info (male, female, yucatan, 20-30 kg, 23 weeks old).

P7731 Carr,A.N., Howard,B.W., Yang,H.T., Eby-Wilkens,E., Loos,P., Varbanov,A., Qu,A., DeMuth,J.P., Davis,M.G., Proia,A., Terjung,R.L., Peters,K.G. Efficacy of systemic administration of SDF-1 in a model of vascular insufficiency: Support for an endothelium-dependent mechanism. Cardiovascular Research 2006; 69(-4-):925-935. >>> Vascular endothelial growth factor; stromal cell-derived factor-1a; PBS; glycerol; sodium acetate; sodium azide; IA (iliac); Rat; 2 weeks; Controls received mp w/ vehicle; dose-response (table 1); cardiovascular; peptides; animal info (adult); bilateral femoral artery ligation; occlusive cardiovascular disease.

P7784 Gaudio,E., Barbaro,B., Alvaro,D., Glaser,S., Francis,H., Ueno,Y., Meininger,C.J., Franchitto,A., Onori,P., Marzioni,M., Taffetani,S., Fava,G., Stoica,G., Venter,J., Reichenbach,R., De Morrow,S., Summers,R., Alpini,G. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 2006; 130(-4-):1270-1282. >>> Vascular endothelial growth factor-A, recomb. mouse; vascular endothelial growth factor-C, recomb. mouse; Saline; BSA; IP; Rat; 1 week; Controls received mp w/ vehicle; peptides; animal info (male, Fischer 344, 150-175g.).

P8017 Kawai,T., Takagi,N., Mochizuki,N., Besshoh,S., Sakanishi,K., Nakahara,M., Takeo,S. Inhibitor of vascular endothelial growth factor receptor tyrosine kinase attenuates cellular proliferation and differentiation to mature neurons in the hippocampal dentate gyrus after transient forebrain ischemia in the adult rat. Neuroscience 2006; 141(-3-):1209-1216. >>> Vascular endothelial growth factor receptor tyrosine kinase inhibitor; DMSO; CSF/CNS (dentate gyrus); Rat; 2001; 7 days; Controls received mp w/ vehicle; dose-response (fig. 4); enzyme inhibitor (VEGF receptor tyrosine kinase); ischemia (transient forebrain); animal info (male, Wistar, 8 weeks old, carotid artery occlusion); 0.5% DMSO; agent also known as 4-[(4'-chloro-2'-fluoro) phenylamino]-6,7-dimethoxyquinazoline; tissue perfusion (dentate gyrus).

P7561 Sun,Y.J., Jin,K.L., Childs,J.T., Xie,L., Mao,X.O., Greenberg,D.A. Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: Evidence from knockout mice and growth factor administration. Developmental Biology 2006; 289(-2-):329-335. >>> Vascular endothelial growth factor-B; CSF, artificial; CSF/CNS; Rat; mice; 1003D; 3 days; Controls received mp w/ vehicle; ischemia (cerebral); animal info (mice, 10-12 wk old; male, Sprague-Dawley).

P7987 Wang,Y.M., Galvan,V., Gorostiza,O., Ataie,M., Jin,K.L., Greenberg,D.A. Vascular endothelial growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral ischemia in the rat. Brain Research 2006; 1115(--):186-193. >>> Vascular endothelial growth factor; CSF, artificial; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; ischemia (cerebral); behavioral study.

P6908 Alonso,G., Galibert,E., Duvoid-Guillou,A., Vincent,A. Hyperosmotic stimulus induces reversible angiogenesis within the hypothalamic magnocellular nuclei of the adult rat: a potential role for neuronal vascular endothelial growth factor. BMC NEUROSCIENCE 2005; 6(--):U1-U19. >>> Antibody, anti-vascular endothelial growth factor; PBS; CSF/CNS (supraoptic nucleus); Rat; 1007D; 6 days; Schematic fig 9; 10 mm, 26 gauge cannula used.

P7495 Burchardt,M., Burchardt,T., Anastasiadis,A.G., Buttyan,R., de la Taille,A., Shabsigh,A., Frank,J., Shabsigh,R. Application of angiogenic factors for therapy of erectile dysfunction: protein and DNA transfer of VEGF 165 into the rat penis. UROLOGY 2005; 66(-3-):665-670. >>> Vascular endothelial growth factor, human 165; Saline, sterile; heparin; IA (renal); Rat; 2004; 28 days; Controls received mp w/ vehicle; functionality of mp verified by VEGF serum immunoassay; comparison of CDNA plasmid micro-injections vs. mp; gene therapy; peptides; animal info (male, Sprague-Dawley); urology; 2000 Units of heparin used.

P7417 Schmidt,N.O., Przylecki,W., Yang,W., Ziu,M., Teng,Y., Kim,S.U., Black,P.M., Aboody,K.S., Carroll,R.S. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. NEOPLASIA 2005; 7(-6-):623-629. >>> Vascular endothelial growth factor, recomb. human; CSF/CNS (parenchyma); Mice; 2004; ; Controls received mp w/ PBS; functionality of mp verified by residual volume; cancer.

P6730 Storkebaum,E., Lambrechts,D., Dewerchin,M., Moreno-Murciano,M.P., Appelmans,S., Oh,H., Van Damme,P., Rutten,B., Man,W.Y., De Mol,M., Wyns,S., Manka,D., Vermeulen,K., Van den Bosch,L., Mertens,N., Schmitz,C., Robberecht,W., Conway,E.M., Collen,D., Moons,L., Carmeliet,P., Carmeliet,P. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nature Neuroscience 2005; 8(-1-):85-92. >>> Vascular endothelial growth factor, recomb. rat; CSF/CNS; Rat; 2004; 100 days; Long-term study; pumps replaced every 28 days; ALZET brain infusion kit used; VEGF was cleared from CSF within 3h; "70-80% of VEGF in pumps remained active after 4 weeks."; neurodegenerative (Amyotrophic Lateral Sclerosis).

P6634 Croll,S.D., Ransohoff,R.M., Cai,N., Zhang,Q., Martin,F.J., Wei,T., Kasselman,L.J., Kintner,J., Murphy,A.J., Yancopoulos,G.D., Wiegand,S.J. VEGF-mediated inflammation precedes angiogenesis in adult brain. Experimental Neurology 2004; 187(-2-):388-402. >>> Vascular endothelial growth factor 164, mouse; Flt-Fc; angiopoietin I, human; angiopoietin II, human; PBS; CSF/CNS (frontoparietal cortex); Rat; 2002; 1,2,3,4,5,7 days; Controls received mp w/ vehicle or hFc; dose-response (fig. 1); brain tissue distribution; peptides; cyanoacrylate adhesive (Loctite 495).

P6614 Kodama,I., Niida,S., Sanada,M., Yoshiko,Y., Tsuda,M., Maeda,N., Ohama,K. Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice. Journal of Bone and Mineral Research 2004; 19(-2-):200-206. >>> Antibody, anti-vascular endothelial growth factor; vascular endothelial growth factor; Flt-1/Fe chimera; SC; Mice; 1002; 2 weeks; Plasma levels taken.

P6370 Manoonkitiwongsa,P.S., Schultz,R.L., McCreery,D.B., Whitter,E.F., Lyden,P.D. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. Journal of Cerebral Blood Flow and Metabolism 2004; 24(-6-):693-702. >>> Vascular endothelial growth factor; Saline; IA (carotid); Rat; 2001; 7 days; Controls received mp w/ vehicle; dose response (p. 697); stroke; ischemia (cerebral); biocompatible glue was used to secure catheter in artery.

P6564 Suzuki,O., Bishop,A.T., Sunagawa,T., Katsube,K., Friedrich,P.F. VEGF-promoted surgical angiogenesis in necrotic bone. MICROSURGERY 2004; 24(-1-):85-91. >>> Vascular endothelial growth factor 165; Phosphate buffer; albumin rabbit serum; Bone; Rabbit; 1003D; 3 days.

top of page

Looking for references? We can help!

ALZET will perform a custom bibliography search for you! ALZET pumps have been used to deliver hundreds of different compounds, including proteins and peptides, in a myriad of different experimental applications. We have recently updated our database, which now contains over 12,000 references that can help you guide your research project!

Order the ALZET SurgicalImplantation Video

Researchers are saying ...

“However formoterol administered intraperitoneally twice a day did not influence LPS-induced premature delivery (data not shown). Osmotic Pumps can maintain the blood concentration of formoterol for over 20h. Thus, it may be of importance that formoterol was continuously and uniformly administered.” (p. 201) Shinkai et al., Reproduction 2003;125:199-203.

ALZET® Osmotic Pumps - Research Applications.

References on the Administration of Growth Factors Using ALZET^® Osmotic Pumps

1. Epidermal Growth Factor

2. Fibroblast Growth Factor

3. Hepatocyte Growth Factor

4. Hepatocyte Growth Factor

5. Insulin-like Growth Factor

6. Nerve Growth Factor

7. Placental Growth Factor

8. Transforming Growth Factor

9. Transforming Growth Factor

10. Vascular Endothelial Growth Factor

Looking for references? We can help!

Researchers are saying ...

ALZET Customer Service-

ALZET® Osmotic Pumps - Research Applications.

References on the Administration of Growth Factors Using ALZET® Osmotic Pumps

1. Epidermal Growth Factor

2. Fibroblast Growth Factor

3. Hepatocyte Growth Factor

4. Hepatocyte Growth Factor

5. Insulin-like Growth Factor

6. Nerve Growth Factor

7. Placental Growth Factor

8. Transforming Growth Factor

9. Transforming Growth Factor

10. Vascular Endothelial Growth Factor

Looking for references? We can help!

Researchers are saying ...

ALZET Customer Service-

References on the Administration of Growth Factors Using ALZET^® Osmotic Pumps